US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
ATE247128T1
(en)
|
1993-09-03 |
2003-08-15 |
Isis Pharmaceuticals Inc |
AMINODERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES
|
US5519134A
(en)
*
|
1994-01-11 |
1996-05-21 |
Isis Pharmaceuticals, Inc. |
Pyrrolidine-containing monomers and oligomers
|
US6184389B1
(en)
*
|
1994-01-11 |
2001-02-06 |
Isis Pharmaceuticals, Inc. |
Combinatorial libraries having aminodiol monomer subunits
|
US5637684A
(en)
*
|
1994-02-23 |
1997-06-10 |
Isis Pharmaceuticals, Inc. |
Phosphoramidate and phosphorothioamidate oligomeric compounds
|
ES2196163T3
(en)
*
|
1995-07-31 |
2003-12-16 |
Shionogi & Co |
PIRROLIDINE DERIVATIVES WITH AN INHIBITION ACTIVITY OF PHOSPHOLIPASE A2.
|
US5854033A
(en)
|
1995-11-21 |
1998-12-29 |
Yale University |
Rolling circle replication reporter systems
|
US20040161777A1
(en)
*
|
1996-06-06 |
2004-08-19 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US20050042647A1
(en)
*
|
1996-06-06 |
2005-02-24 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
US20040171028A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
WO2005121368A1
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Chimeric gapped oligomeric compositions
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US20040266706A1
(en)
*
|
2002-11-05 |
2004-12-30 |
Muthiah Manoharan |
Cross-linked oligomeric compounds and their use in gene modulation
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US9096636B2
(en)
*
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US6111085A
(en)
*
|
1996-09-13 |
2000-08-29 |
Isis Pharmaceuticals, Inc. |
Carbamate-derivatized nucleosides and oligonucleosides
|
US5908845A
(en)
*
|
1996-10-30 |
1999-06-01 |
Segev; David |
Polyether nucleic acids
|
US6395539B1
(en)
|
1997-05-05 |
2002-05-28 |
Ohio University |
Composition and methods for bioremediation
|
US6551814B1
(en)
|
1997-05-05 |
2003-04-22 |
Ohio University |
Methods for bioremediation by degrading toluene
|
WO1999001579A1
(en)
|
1997-07-01 |
1999-01-14 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
US7252950B1
(en)
|
1997-09-04 |
2007-08-07 |
The Regents Of The University Of California |
Assays for detecting modulators of cytoskeletal function
|
WO1999047923A2
(en)
|
1998-03-20 |
1999-09-23 |
The Rockefeller University |
Assays for screening compounds which interact with cation channel proteins, mutant prokaryotic cation channel proteins, and uses thereof
|
US7321828B2
(en)
*
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
US20040186071A1
(en)
*
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
US6410687B1
(en)
|
1998-04-14 |
2002-06-25 |
The Regents Of The University Of California |
Polypeptides for the detection of microtubule depolymerization inhibitors
|
US6699969B1
(en)
|
1998-04-14 |
2004-03-02 |
The Regents Of The University Of California |
Assays for the detection of microtubule depolymerization inhibitors
|
US6872537B1
(en)
|
1998-04-14 |
2005-03-29 |
Regents Of The University Of California |
Assays for the detection of microtubule depolymerization inhibitors
|
US6841539B1
(en)
*
|
1998-05-21 |
2005-01-11 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for topical delivery of oligonucleotides
|
EP1080103A4
(en)
*
|
1998-05-21 |
2003-07-02 |
Isis Pharmaceuticals Inc |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
US7459473B2
(en)
|
1998-06-03 |
2008-12-02 |
Glia Med, Inc. |
N-linked sulfonamides of N-heterocyclic carboxylic acids or carboxylic acid isosteres
|
US6288234B1
(en)
*
|
1998-06-08 |
2001-09-11 |
Advanced Medicine, Inc. |
Multibinding inhibitors of microsomal triglyceride transferase protein
|
US6335439B1
(en)
|
1998-06-11 |
2002-01-01 |
Isis Pharmaceuticals, Inc. |
Method of preparing phosphoramidites
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US7402400B2
(en)
|
2001-07-03 |
2008-07-22 |
Regents Of The University Of California |
Mammalian sweet taste receptors
|
US6225293B1
(en)
|
1998-09-02 |
2001-05-01 |
Isis Pharmaceuticals, Inc. |
Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
AU772847B2
(en)
|
1998-11-12 |
2004-05-06 |
Invitrogen Corporation |
Transfection reagents
|
US6492111B1
(en)
|
1998-11-25 |
2002-12-10 |
Isis Pharmaceuticals, Inc. |
In situ binary synthesis of biologically effective molecules
|
US6300320B1
(en)
|
1999-01-05 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Modulation of c-jun using inhibitors of protein kinase C
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
EP1185871A4
(en)
|
1999-06-01 |
2003-01-15 |
Caliper Techn Corp |
Microscale assays and microfluidic devices for transporter, gradient induced, and binding activities
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US6593466B1
(en)
*
|
1999-07-07 |
2003-07-15 |
Isis Pharmaceuticals, Inc. |
Guanidinium functionalized nucleotides and precursors thereof
|
US6147200A
(en)
*
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
US6617442B1
(en)
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
US7332275B2
(en)
|
1999-10-13 |
2008-02-19 |
Sequenom, Inc. |
Methods for detecting methylated nucleotides
|
EP1950306A1
(en)
|
1999-11-17 |
2008-07-30 |
Mendel Biotechnology, Inc. |
Environmental stress tolerance genes
|
EP1229782B1
(en)
|
1999-11-17 |
2012-11-07 |
Mendel Biotechnology, Inc. |
Pathogen tolerance genes
|
US6458538B1
(en)
|
1999-12-14 |
2002-10-01 |
Ptc Therapeutics, Inc. |
Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
|
US8642284B1
(en)
|
1999-12-15 |
2014-02-04 |
Massachusetts Institute Of Technology |
Methods for identifying agents that alter NAD-dependent deacetylation activity of a SIR2 protein
|
US7452664B2
(en)
*
|
1999-12-15 |
2008-11-18 |
Massachusetts Institute Of Technology |
Methods for identifying agents which alter histone protein acetylation
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US20030176385A1
(en)
*
|
2000-02-15 |
2003-09-18 |
Jingfang Ju |
Antisense modulation of protein expression
|
TW201006846A
(en)
|
2000-03-07 |
2010-02-16 |
Senomyx Inc |
T1R taste receptor and genes encidung same
|
EP1274726B1
(en)
*
|
2000-04-13 |
2009-12-23 |
Thomas N. Wight |
Therapeutic compounds and methods for modulating v3, a versican isoform
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
US20060166227A1
(en)
*
|
2000-06-20 |
2006-07-27 |
Stephen Kingsmore |
Protein expression profiling
|
US6323009B1
(en)
*
|
2000-06-28 |
2001-11-27 |
Molecular Staging, Inc. |
Multiply-primed amplification of nucleic acid sequences
|
US6958214B2
(en)
|
2000-07-10 |
2005-10-25 |
Sequenom, Inc. |
Polymorphic kinase anchor proteins and nucleic acids encoding the same
|
WO2002015675A1
(en)
|
2000-08-22 |
2002-02-28 |
Mendel Biotechnology, Inc. |
Genes for modifying plant traits iv
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
AU2001296846B2
(en)
|
2000-10-12 |
2007-07-05 |
University Of Rochester |
Compositions that inhibit proliferation of cancer cells
|
US7045283B2
(en)
|
2000-10-18 |
2006-05-16 |
The Regents Of The University Of California |
Methods of high-throughput screening for internalizing antibodies
|
WO2002034879A2
(en)
*
|
2000-10-27 |
2002-05-02 |
Invitrogen Corporation |
Method for introducing antisense oligonucleotides into eucaryotic cells
|
US7572575B2
(en)
|
2000-12-13 |
2009-08-11 |
Massachusetts Institute Of Technology |
SIR2 activity
|
TW201022287A
(en)
|
2001-01-03 |
2010-06-16 |
Senomyx Inc |
T1R taste receptors and genes encoding same
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7883856B2
(en)
|
2001-04-05 |
2011-02-08 |
Senomyx Inc. |
Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
|
US20030191073A1
(en)
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
MXPA03009580A
(en)
*
|
2001-04-20 |
2004-12-06 |
Sinai School Medicine |
T1r3 a novel taste receptor.
|
US7803982B2
(en)
|
2001-04-20 |
2010-09-28 |
The Mount Sinai School Of Medicine Of New York University |
T1R3 transgenic animals, cells and related methods
|
US20030194798A1
(en)
|
2001-05-24 |
2003-10-16 |
Surber Mark W. |
Minicell compositions and methods
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
MXPA03011985A
(en)
|
2001-06-20 |
2004-03-26 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor.
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
CA2451643C
(en)
|
2001-06-21 |
2012-11-13 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
EP2003451B1
(en)
|
2001-06-26 |
2012-05-30 |
Senomyx, Inc. |
T1r1-t1r3 hetero-oligomeric umami taste receptors and cell lines that express said receptors and use thereof for identification of umami taste compounds
|
IL159640A0
(en)
|
2001-07-10 |
2004-06-01 |
Senomyx Inc |
Use of specific t2r taste receptors to identify compounds that block bitter taste
|
WO2003009815A2
(en)
*
|
2001-07-25 |
2003-02-06 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for modulating blood-brain barrier transport
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
ES2390531T3
(en)
|
2001-09-18 |
2012-11-13 |
Genentech, Inc. |
Compositions and procedures for the diagnosis and treatment of tumor
|
NZ585001A
(en)
|
2001-10-09 |
2011-08-26 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
EP1442117A4
(en)
*
|
2001-10-12 |
2005-04-27 |
Univ California |
Gastrointestinal chemosensory receptors
|
US20030170678A1
(en)
*
|
2001-10-25 |
2003-09-11 |
Neurogenetics, Inc. |
Genetic markers for Alzheimer's disease and methods using the same
|
WO2003054143A2
(en)
*
|
2001-10-25 |
2003-07-03 |
Neurogenetics, Inc. |
Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
|
US20030224380A1
(en)
*
|
2001-10-25 |
2003-12-04 |
The General Hospital Corporation |
Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
|
US7871619B2
(en)
|
2001-11-30 |
2011-01-18 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
WO2003048341A2
(en)
*
|
2001-12-03 |
2003-06-12 |
Uab Research Foundation |
Cap-gly domain structure and uses thereof
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
EP2067472A1
(en)
|
2002-01-02 |
2009-06-10 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
JP2005523688A
(en)
*
|
2002-01-18 |
2005-08-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
Identification of polynucleotides and polypeptides for predicting the activity of protein tyrosine kinases and / or compounds that interact with protein tyrosine kinase pathways
|
JP2005515780A
(en)
|
2002-02-01 |
2005-06-02 |
セクイター インコーポレイテッド |
Double stranded oligonucleotide
|
EP1572902B1
(en)
*
|
2002-02-01 |
2014-06-11 |
Life Technologies Corporation |
HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
US7553619B2
(en)
*
|
2002-02-08 |
2009-06-30 |
Qiagen Gmbh |
Detection method using dissociated rolling circle amplification
|
EP1572906A4
(en)
|
2002-03-04 |
2008-05-28 |
Bristol Myers Squibb Co |
Novel nucleic acid molecules and polypeptides encoding baboon tafi
|
US7169916B2
(en)
*
|
2002-04-01 |
2007-01-30 |
Isis Pharmaceuticals, Inc. |
Chloral-free DCA in oligonucleotide synthesis
|
NZ535925A
(en)
|
2002-04-16 |
2008-06-30 |
Genentech Inc |
An isolated antibody that binds to a particular polypeptide
|
US7432342B2
(en)
*
|
2002-05-03 |
2008-10-07 |
Sequenom, Inc. |
Kinase anchor protein muteins, peptides thereof and related documents
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
KR100527334B1
(en)
*
|
2002-06-07 |
2005-11-09 |
(주)넥스젠 |
Novel Linker for Oligonucleotides
|
US20040248094A1
(en)
*
|
2002-06-12 |
2004-12-09 |
Ford Lance P. |
Methods and compositions relating to labeled RNA molecules that reduce gene expression
|
US20100075423A1
(en)
*
|
2002-06-12 |
2010-03-25 |
Life Technologies Corporation |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
US7893218B2
(en)
|
2003-06-16 |
2011-02-22 |
Stowers Institute For Medical Research |
Antibodies that specifically bind SOST peptides
|
US20040092470A1
(en)
*
|
2002-06-18 |
2004-05-13 |
Leonard Sherry A. |
Dry powder oligonucleotide formualtion, preparation and its uses
|
CA2495478A1
(en)
|
2002-08-05 |
2004-02-12 |
University Of Rochester |
Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
US20040081653A1
(en)
|
2002-08-16 |
2004-04-29 |
Raitano Arthur B. |
Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
|
JP2005538186A
(en)
|
2002-09-13 |
2005-12-15 |
レプリコール インコーポレーティッド |
Non-sequence complementary antiviral oligonucleotides
|
EP3249046B1
(en)
|
2002-09-18 |
2020-07-08 |
Mendel Biotechnology, Inc. |
Polynucleotides and polypeptides in plants
|
JP2006500030A
(en)
|
2002-09-20 |
2006-01-05 |
イェール ユニバーシティ |
Riboswitch, method of using the same, and composition for use with riboswitch
|
EP1549767A4
(en)
|
2002-09-26 |
2006-06-07 |
Amgen Inc |
Modulation of forkhead box o1a expression
|
UA80841C2
(en)
|
2002-10-07 |
2007-11-12 |
Univ California |
Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants)
|
JP2006515318A
(en)
*
|
2002-10-29 |
2006-05-25 |
ファルマシア・コーポレーション |
Specifically associated cancer-related gene, polypeptide encoded thereby and method of use thereof
|
EP1578765A4
(en)
|
2002-11-05 |
2008-04-23 |
Isis Pharmaceuticals Inc |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US9150606B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
EP1560839A4
(en)
|
2002-11-05 |
2008-04-23 |
Isis Pharmaceuticals Inc |
Chimeric oligomeric compounds and their use in gene modulation
|
US9150605B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
EP1569695B1
(en)
|
2002-11-13 |
2013-05-15 |
Genzyme Corporation |
Antisense modulation of apolipoprotein b expression
|
DK2336318T3
(en)
|
2002-11-13 |
2013-07-15 |
Genzyme Corp |
ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
|
JP4915980B2
(en)
|
2002-11-15 |
2012-04-11 |
エムユーエスシー ファウンデーション フォー リサーチ デベロップメント |
Complement receptor 2 targeted complement regulator
|
WO2004046330A2
(en)
*
|
2002-11-15 |
2004-06-03 |
Morphotek, Inc. |
Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
|
WO2004046332A2
(en)
*
|
2002-11-19 |
2004-06-03 |
Amgen Inc. |
Amplified genes involved in cancer
|
US7557092B2
(en)
|
2002-11-21 |
2009-07-07 |
University Of Utah Research Foundation |
Purinergic modulation of smell
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
CA2510587A1
(en)
|
2002-12-20 |
2004-07-15 |
Qiagen Gmbh |
Nucleic acid amplification
|
US9487823B2
(en)
|
2002-12-20 |
2016-11-08 |
Qiagen Gmbh |
Nucleic acid amplification
|
US6977153B2
(en)
*
|
2002-12-31 |
2005-12-20 |
Qiagen Gmbh |
Rolling circle amplification of RNA
|
EP1585815A4
(en)
*
|
2003-01-21 |
2006-02-22 |
Bristol Myers Squibb Co |
Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof
|
CA2515484C
(en)
|
2003-02-11 |
2011-09-20 |
Antisense Therapeutics Ltd |
Modulation of insulin like growth factor i receptor expression
|
US7002006B2
(en)
*
|
2003-02-12 |
2006-02-21 |
Isis Pharmaceuticals, Inc. |
Protection of nucleosides
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20070141570A1
(en)
*
|
2003-03-07 |
2007-06-21 |
Sequenom, Inc. |
Association of polymorphic kinase anchor proteins with cardiac phenotypes and related methods
|
AU2004220556B2
(en)
|
2003-03-07 |
2009-05-07 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US8043834B2
(en)
|
2003-03-31 |
2011-10-25 |
Qiagen Gmbh |
Universal reagents for rolling circle amplification and methods of use
|
US20070179100A1
(en)
*
|
2003-04-09 |
2007-08-02 |
Muthiah Manoharan |
Protected monomers
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
EP2664672A1
(en)
|
2003-04-17 |
2013-11-20 |
Alnylam Pharmaceuticals Inc. |
Modified iRNA agents
|
US8796436B2
(en)
|
2003-04-17 |
2014-08-05 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
US7723509B2
(en)
*
|
2003-04-17 |
2010-05-25 |
Alnylam Pharmaceuticals |
IRNA agents with biocleavable tethers
|
US7851615B2
(en)
*
|
2003-04-17 |
2010-12-14 |
Alnylam Pharmaceuticals, Inc. |
Lipophilic conjugated iRNA agents
|
US8017762B2
(en)
*
|
2003-04-17 |
2011-09-13 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
ATE541052T1
(en)
|
2003-05-30 |
2012-01-15 |
Agensys Inc |
VARIANTS OF PROSTATE STEM CELL ANTIGEN (PSCA) AND PARTIAL SEQUENCES THEREOF
|
WO2004108081A2
(en)
*
|
2003-06-02 |
2004-12-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide synthesis with alternative solvents
|
WO2005002507A2
(en)
|
2003-06-03 |
2005-01-13 |
Isis Pharmaceuticals, Inc. |
Modulation of survivin expression
|
DK3604537T3
(en)
|
2003-06-13 |
2022-02-28 |
Alnylam Europe Ag |
Double-stranded ribonucleic acid with increased efficiency in an organism
|
WO2004112575A2
(en)
*
|
2003-06-20 |
2004-12-29 |
Amgen Inc. |
Gene amplification and overexpression in cancer
|
WO2004113496A2
(en)
*
|
2003-06-20 |
2004-12-29 |
Isis Pharmaceuticals, Inc. |
Double stranded compositions comprising a 3’-endo modified strand for use in gene modulation
|
WO2005002527A2
(en)
*
|
2003-07-03 |
2005-01-13 |
Massachusetts Institute Of Technology |
Sirt1 modulation of adipogenesis and adipose function
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
AR046078A1
(en)
|
2003-08-06 |
2005-11-23 |
Senomyx Inc |
NEW FLAVORS, FLAVORS MODIFIERS, GUSTATIVE SUBSTANCES, TASTE IMPROVERS, GUSTATIVE SUBSTANCES AND / OR IMPROVEMENTS OF UMANI OR SWEET TASTE AND USE OF THE SAME.
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
US20050053981A1
(en)
*
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
EP2182063A3
(en)
|
2003-09-18 |
2012-07-18 |
Isis Pharmaceuticals, Inc. |
Modulation of EIF4E expression
|
AU2004274021B2
(en)
*
|
2003-09-18 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
4'-thionucleosides and oligomeric compounds
|
US20050244810A1
(en)
*
|
2003-09-29 |
2005-11-03 |
Egan Josephine M |
Taste signaling in gastrointestinal cells
|
US7480382B2
(en)
*
|
2003-09-30 |
2009-01-20 |
Microsoft Corporation |
Image file container
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
US7794948B2
(en)
|
2003-11-07 |
2010-09-14 |
Vermilllion, Inc. |
Biomarkers for alzheimer's disease
|
JP4901478B2
(en)
|
2003-11-17 |
2012-03-21 |
ジェネンテック, インコーポレイテッド |
Compositions and methods for the treatment of tumors of hematopoietic origin
|
US20050164969A1
(en)
*
|
2003-11-19 |
2005-07-28 |
Massachusetts Institute Of Technology |
Method of extending life span
|
EP2322637B1
(en)
|
2003-12-24 |
2016-05-18 |
Novo Nordisk A/S |
Transgenic mouse comprising a polynucleotide encoding human or humanized C5AR
|
EP1711606A2
(en)
|
2004-01-20 |
2006-10-18 |
Isis Pharmaceuticals, Inc. |
Modulation of glucocorticoid receptor expression
|
US7468431B2
(en)
*
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US8778900B2
(en)
*
|
2004-01-22 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP1 expression
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
EP2700720A3
(en)
|
2004-03-15 |
2015-01-28 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNASE H
|
PL1734996T3
(en)
|
2004-04-02 |
2013-09-30 |
Univ California |
Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
|
WO2005097817A2
(en)
|
2004-04-05 |
2005-10-20 |
Alnylam Pharmaceuticals, Inc. |
Process and reagents for oligonucleotide synthesis and purification
|
US20050244869A1
(en)
*
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
US20050260755A1
(en)
*
|
2004-04-06 |
2005-11-24 |
Isis Pharmaceuticals, Inc. |
Sequential delivery of oligomeric compounds
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
CA2562685C
(en)
*
|
2004-04-27 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
|
US7674778B2
(en)
|
2004-04-30 |
2010-03-09 |
Alnylam Pharmaceuticals |
Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
|
US7939251B2
(en)
|
2004-05-06 |
2011-05-10 |
Roche Molecular Systems, Inc. |
SENP1 as a marker for cancer
|
DK1773872T3
(en)
|
2004-05-21 |
2017-05-08 |
Uab Res Found |
VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof
|
US7323347B2
(en)
*
|
2004-05-27 |
2008-01-29 |
Sensata Technologies, Inc. |
Biosensor surface structures and methods
|
EP2471922A1
(en)
|
2004-05-28 |
2012-07-04 |
Asuragen, Inc. |
Methods and compositions involving microRNA
|
EP2583981A3
(en)
|
2004-05-28 |
2013-07-31 |
Agensys, Inc. |
Antibodies and related molecules that bind to PSCA proteins
|
AU2005252662B2
(en)
*
|
2004-06-03 |
2011-08-18 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
EP2453024B1
(en)
|
2004-06-21 |
2017-12-06 |
The Board of Trustees of The Leland Stanford Junior University |
Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
|
FR2873495B1
(en)
*
|
2004-07-23 |
2006-10-20 |
Accumulateurs Fixes |
SAFETY DEVICE FOR SEALED ACCUMULATOR
|
EP2990410A1
(en)
|
2004-08-10 |
2016-03-02 |
Alnylam Pharmaceuticals Inc. |
Chemically modified oligonucleotides
|
EP1786430B1
(en)
*
|
2004-08-20 |
2013-04-03 |
Buck Institute for Age Research |
Small molecules that replace or agonize p53 function
|
WO2006023880A2
(en)
*
|
2004-08-23 |
2006-03-02 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
JP2008511678A
(en)
|
2004-09-02 |
2008-04-17 |
イェール ユニバーシティ |
Regulation of oncogene by microRNA
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
ES2729826T3
(en)
|
2004-09-23 |
2019-11-06 |
Arc Medical Devices Inc |
Pharmaceutical compositions and related methods to inhibit fibrous adhesions or inflammatory disease using low sulfate fucans
|
CA2584614A1
(en)
|
2004-10-20 |
2006-08-24 |
Antisense Therapeutics Ltd |
Antisense modulation of integrin .alpha.4 expression
|
EP2322616A1
(en)
|
2004-11-12 |
2011-05-18 |
Asuragen, Inc. |
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
US20060275792A1
(en)
*
|
2004-11-15 |
2006-12-07 |
Lee Jun E |
Enhancement of nucleic acid amplification using double-stranded DNA binding proteins
|
US20060105348A1
(en)
*
|
2004-11-15 |
2006-05-18 |
Lee Jun E |
Compositions and methods for the detection and discrimination of nucleic acids
|
US20100256062A1
(en)
|
2004-12-06 |
2010-10-07 |
Howard Tommy E |
Allelic Variants of Human Factor VIII
|
US7850960B2
(en)
|
2004-12-30 |
2010-12-14 |
University Of Washington |
Methods for regulation of stem cells
|
US20100196509A1
(en)
|
2005-02-28 |
2010-08-05 |
Jonathan Braun |
Methods for Diagnosis and Treatment of Endometrial Cancer
|
CN101175769A
(en)
|
2005-03-10 |
2008-05-07 |
健泰科生物技术公司 |
Methods and compositions for modulating vascular integrity
|
US7476733B2
(en)
*
|
2005-03-25 |
2009-01-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
|
EP1871913A2
(en)
*
|
2005-03-25 |
2008-01-02 |
Ambion, Inc. |
Methods and compositions for depleting abundant rna transcripts
|
AU2006230563B8
(en)
|
2005-03-31 |
2010-06-17 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161P2F10B proteins
|
US8309303B2
(en)
|
2005-04-01 |
2012-11-13 |
Qiagen Gmbh |
Reverse transcription and amplification of RNA with simultaneous degradation of DNA
|
US8318906B2
(en)
|
2005-04-15 |
2012-11-27 |
The Regents Of The University Of California |
EMP2 antibodies and their therapeutic uses
|
US20070099830A1
(en)
|
2005-04-21 |
2007-05-03 |
Massachusetts Institute Of Technology |
Sirt4 activities
|
WO2007008300A2
(en)
|
2005-05-31 |
2007-01-18 |
ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE |
Triblock copolymers for cytoplasmic delivery of gene-based drugs
|
US20090209621A1
(en)
|
2005-06-03 |
2009-08-20 |
The Johns Hopkins University |
Compositions and methods for decreasing microrna expression for the treatment of neoplasia
|
WO2006138145A1
(en)
|
2005-06-14 |
2006-12-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
WO2007002528A1
(en)
*
|
2005-06-23 |
2007-01-04 |
Yale University |
Anti-aging micrornas
|
EP1904093B1
(en)
|
2005-07-19 |
2018-06-13 |
Stemgen S.P.A. |
Inhibition of the tumorigenic potential of tumor stem cells by bmp-4
|
WO2007016597A2
(en)
*
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
|
ATE483802T1
(en)
|
2005-08-11 |
2010-10-15 |
Synthetic Genomics Inc |
METHOD FOR IN VITRO RECOMBINATION
|
EP1915461B1
(en)
|
2005-08-17 |
2018-08-01 |
Dx4U GmbH |
Composition and method for determination of ck19 expression
|
AU2006284855B2
(en)
|
2005-08-29 |
2011-10-13 |
Regulus Therapeutics Inc. |
Methods for use in modulating miR-122a
|
US20090203893A1
(en)
|
2005-08-29 |
2009-08-13 |
Regulus Therapeutics, Llc |
Antisense compounds having enhanced anti-microrna activity
|
US7943134B2
(en)
*
|
2005-08-31 |
2011-05-17 |
Academia Sinica |
Compositions and methods for identifying response targets and treating flavivirus infection responses
|
TWI333959B
(en)
*
|
2005-08-31 |
2010-12-01 |
Academia Sinica |
Methods and reagents for the analysis and purification of polysaccharides
|
EP1762627A1
(en)
|
2005-09-09 |
2007-03-14 |
Qiagen GmbH |
Method for the activation of a nucleic acid for performing a polymerase reaction
|
US7781209B2
(en)
*
|
2005-09-25 |
2010-08-24 |
Multispan, Inc. |
GPCR-expressing cell lines
|
EP1934331A4
(en)
|
2005-10-14 |
2009-01-21 |
Musc Found For Res Dev |
Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
MX2007015931A
(en)
|
2005-10-20 |
2008-04-22 |
Senomyx Inc |
Chimeric human sweet-umami and umami-sweet taste receptors.
|
AU2006305886C1
(en)
*
|
2005-10-28 |
2011-03-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of huntingtin gene
|
ES2317819T1
(en)
*
|
2005-11-03 |
2009-05-01 |
Redpoint Bio Corporation |
HIGH PERFORMANCE DETECTION TEST FOR THE TRPM5 ION CHANNEL.
|
EP1942948A4
(en)
*
|
2005-11-04 |
2010-03-03 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of nav1.8 gene
|
BRPI0618338A2
(en)
|
2005-11-07 |
2011-08-23 |
Scripps Resarch Inst |
use of tissue factor signaling inhibitor, method for identifying an agent that inhibits tf / viia signaling, pharmaceutical compositions and kit
|
US20100069461A1
(en)
|
2005-11-09 |
2010-03-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
WO2007059064A2
(en)
|
2005-11-12 |
2007-05-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Fgf2-related methods for diagnosing and treating depression
|
JP2009516710A
(en)
|
2005-11-21 |
2009-04-23 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
Modulating the expression of eIF4E-BP2
|
US8278104B2
(en)
*
|
2005-12-13 |
2012-10-02 |
Kyoto University |
Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
|
US8129187B2
(en)
*
|
2005-12-13 |
2012-03-06 |
Kyoto University |
Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
|
US20090227032A1
(en)
*
|
2005-12-13 |
2009-09-10 |
Kyoto University |
Nuclear reprogramming factor and induced pluripotent stem cells
|
EA018039B1
(en)
*
|
2005-12-13 |
2013-05-30 |
Киото Юниверсити |
Nuclear reprogramming factor
|
WO2007100412A2
(en)
*
|
2005-12-21 |
2007-09-07 |
Yale University |
Methods and compositions related to the modulation of riboswitches
|
CN101437933B
(en)
|
2005-12-28 |
2013-11-06 |
斯克里普斯研究所 |
Natural antisense and non-coding RNA transcripts as drug targets
|
PT2161038E
(en)
|
2006-01-26 |
2014-03-10 |
Isis Pharmaceuticals Inc |
Compositions and their uses directed to huntingtin
|
EP2314594B1
(en)
*
|
2006-01-27 |
2014-07-23 |
Isis Pharmaceuticals, Inc. |
6-modified bicyclic nucleic acid analogs
|
US8129515B2
(en)
|
2006-01-27 |
2012-03-06 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of microRNAs
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
US20090036429A1
(en)
*
|
2006-02-17 |
2009-02-05 |
Ohler Norman E |
Hydroxypiperidine Derivatives and Uses Thereof
|
US20100278821A1
(en)
|
2006-03-21 |
2010-11-04 |
The Regents Of The University Of California |
N-cadherin: target for cancer diagnosis and therapy
|
EP2390666A1
(en)
|
2006-03-21 |
2011-11-30 |
The Regents of The University of California |
N-Cadherin as target for cancer diagnosis and therapy
|
US20070232556A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Montine Thomas J |
Methods and compositions for the treatment of neurological diseases and disorders
|
KR101547579B1
(en)
|
2006-03-31 |
2015-08-27 |
알닐람 파마슈티칼스 인코포레이티드 |
DsRNA for inhibiting expression of Eg5 gene
|
EP3398452A3
(en)
|
2006-04-21 |
2018-11-28 |
Senomyx, Inc. |
Comestible compositions comprising high potency savory flavorants, and processes for producing them
|
WO2007129598A1
(en)
|
2006-05-02 |
2007-11-15 |
Teikyo University |
Method for screening of substance capable of increasing glutathione
|
CA2651031A1
(en)
*
|
2006-05-03 |
2007-11-08 |
Baltic Technology Development, Ltd. |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
EP2527442A3
(en)
|
2006-05-05 |
2013-03-06 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating gene expression
|
US20090326041A1
(en)
|
2006-05-05 |
2009-12-31 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of sglt2
|
DK2066684T3
(en)
|
2006-05-11 |
2012-10-22 |
Isis Pharmaceuticals Inc |
5'-Modified Bicyclic Nucleic Acid Analogs
|
US7666854B2
(en)
*
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
CN101489566B
(en)
|
2006-05-19 |
2012-04-18 |
阿尔尼拉姆医药品有限公司 |
Rnai modulation of aha and therapeutic uses thereof
|
CA2653451C
(en)
|
2006-05-22 |
2015-12-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of ikk-b gene
|
WO2007137301A2
(en)
*
|
2006-05-23 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Modulation of chrebp expression
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
ATE502121T1
(en)
*
|
2006-06-06 |
2011-04-15 |
Massachusetts Inst Technology |
CHOLESTEROL-REGULATING COMPLEX OF SIRT1 AND LXR AND ITS USE
|
EP1865316B1
(en)
|
2006-06-07 |
2010-02-24 |
Nutrinova Nutrition Specialties & Food Ingredients GmbH |
Screening methods for compounds that modulate the activity of G-protein coupled receptors
|
US9506056B2
(en)
*
|
2006-06-08 |
2016-11-29 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
RU2009102155A
(en)
|
2006-06-30 |
2010-08-10 |
Апплера Корпорейшн (Us) |
METHODS FOR ANALYZING BINDING INTERACTIONS
|
US8198253B2
(en)
|
2006-07-19 |
2012-06-12 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to HBXIP
|
WO2008013861A2
(en)
*
|
2006-07-27 |
2008-01-31 |
Redpoint Bio Corporation |
Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
|
EP2057284A4
(en)
*
|
2006-08-04 |
2011-06-29 |
Isis Pharmaceuticals Inc |
Compositions and methods for the modulation of jnk proteins
|
WO2008022035A2
(en)
*
|
2006-08-10 |
2008-02-21 |
The Scripps Research Institute |
Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal
|
WO2008019394A2
(en)
*
|
2006-08-11 |
2008-02-14 |
The Government Of The United States Of America As Represented By The Secretary, Dept Of Health And Human Services |
Methods for treatment and diagnosis of psychiatric disorders
|
EP2423332A1
(en)
|
2006-08-25 |
2012-02-29 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
NZ575090A
(en)
|
2006-09-06 |
2012-02-24 |
Univ California |
Molecular diagnosis and classification of malignant melanoma using RGS1, ARPC2, FN1, SPP1 and WNT-2 polypeptide markers
|
US20080089845A1
(en)
*
|
2006-09-07 |
2008-04-17 |
N.V. Organon |
Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
|
EP2061799A4
(en)
*
|
2006-09-11 |
2010-12-22 |
Univ Yale |
Methods and compositions for the use of lysine riboswitches
|
WO2008036776A2
(en)
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
US20090131348A1
(en)
|
2006-09-19 |
2009-05-21 |
Emmanuel Labourier |
Micrornas differentially expressed in pancreatic diseases and uses thereof
|
JP5560039B2
(en)
|
2006-10-05 |
2014-07-23 |
マサチューセッツ インスティテュート オブ テクノロジー |
Multi-functional coded particles for high-throughput analysis
|
AU2007310989B2
(en)
|
2006-10-18 |
2014-05-29 |
Isis Pharmaceuticals, Inc. |
Antisense compounds
|
WO2008136852A2
(en)
|
2006-11-01 |
2008-11-13 |
University Of Rochester |
Methods and compositions related to the structure and function of apobec3g
|
US20100062000A1
(en)
*
|
2006-11-21 |
2010-03-11 |
The Regents Of The University Of California |
Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
CA2670563A1
(en)
*
|
2006-11-27 |
2008-06-05 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
CA2672297A1
(en)
|
2006-12-11 |
2008-06-19 |
University Of Utah Research Foundation |
Compositions and methods for treating pathologic angiogenesis and vascular permeability
|
EP2114396A4
(en)
*
|
2006-12-29 |
2010-03-10 |
Salk Inst For Biological Studi |
Methods for enhancing exercise performance
|
EP2121987B1
(en)
*
|
2007-02-09 |
2012-06-13 |
Northwestern University |
Particles for detecting intracellular targets
|
CA2679586A1
(en)
*
|
2007-02-27 |
2008-10-23 |
Northwestern University |
Molecule attachment to nanoparticles
|
US20080229436A1
(en)
*
|
2007-03-15 |
2008-09-18 |
Board Of Trustees Of The University Of Arkansas |
Methods for identifying modulators of lifespan and resistance to oxidative stress
|
KR20100015757A
(en)
|
2007-03-22 |
2010-02-12 |
예일 유니버시티 |
Methods and compositions related to riboswitches that control alternative splicing
|
JP5350360B2
(en)
|
2007-03-29 |
2013-11-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Compositions and methods for inhibiting the expression of genes from Ebola
|
EP2141994A4
(en)
*
|
2007-04-26 |
2011-05-18 |
Avalon Pharmaceuticals |
Multi-ring compounds and uses thereof
|
WO2008141275A1
(en)
|
2007-05-11 |
2008-11-20 |
The Johns Hopkins University |
Biomarkers for melanoma
|
CN105748480A
(en)
|
2007-05-11 |
2016-07-13 |
宾夕法尼亚大学理事会 |
Methods of treatment of skin ulcers
|
EP2977452A3
(en)
|
2007-05-11 |
2016-05-25 |
Thomas Jefferson University |
Methods of treatment and prevention of neurodegenerative diseases and disorders
|
CA2687684A1
(en)
*
|
2007-05-29 |
2008-12-11 |
Yale University |
Methods and compositions related to riboswitches that control alternative splicing and rna processing
|
MX2009012773A
(en)
*
|
2007-05-29 |
2009-12-16 |
Univ Yale |
Riboswitches and methods and compositions for use of and with riboswitches.
|
AU2008260277C1
(en)
|
2007-05-30 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
IN2009KN04568A
(en)
|
2007-06-01 |
2015-08-28 |
Univ Princeton |
|
US7807372B2
(en)
*
|
2007-06-04 |
2010-10-05 |
Northwestern University |
Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
|
DK2173760T4
(en)
|
2007-06-08 |
2016-02-08 |
Isis Pharmaceuticals Inc |
Carbocyclic bicyclic nukleinsyreanaloge
|
JP2008307007A
(en)
*
|
2007-06-15 |
2008-12-25 |
Bayer Schering Pharma Ag |
Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
|
US9213999B2
(en)
*
|
2007-06-15 |
2015-12-15 |
Kyoto University |
Providing iPSCs to a customer
|
ES2376507T5
(en)
*
|
2007-07-05 |
2015-08-31 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
ES2477293T3
(en)
|
2007-08-13 |
2014-07-16 |
Baxter International Inc. |
IVIG modulation of chemokines for the treatment of multiple sclerosis, Alzheimer's disease and Parkinson's disease
|
EP2188298B1
(en)
|
2007-08-15 |
2013-09-18 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
KR101599715B1
(en)
|
2007-08-21 |
2016-03-08 |
세노믹스, 인코포레이티드 |
Human T2R bitterness receptors and uses thereof
|
EP2190478B1
(en)
|
2007-08-24 |
2016-03-23 |
Oncotherapy Science, Inc. |
Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
|
JP2010537638A
(en)
|
2007-08-28 |
2010-12-09 |
ユーエービー リサーチ ファウンデーション |
Synthetic apolipoprotein E mimetic polypeptides and methods of use
|
DK2682400T5
(en)
|
2007-08-28 |
2017-11-27 |
Uab Research Foundation |
Synthetic apolipoprotein E mimic polypeptides and methods of use
|
WO2009039466A1
(en)
|
2007-09-20 |
2009-03-26 |
Vanderbilt University |
Free solution measurement of molecular interactions by backscattering interferometry
|
WO2009039442A1
(en)
*
|
2007-09-21 |
2009-03-26 |
California Institute Of Technology |
Nfia in glial fate determination, glioma therapy and astrocytoma treatment
|
WO2009045377A2
(en)
*
|
2007-10-01 |
2009-04-09 |
Redpoint Bio Corporation |
A non-desensitizing mutant of the transient receptor potential trpm5 ion channel
|
WO2009046407A2
(en)
|
2007-10-04 |
2009-04-09 |
Zymogenetics, Inc. |
B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
|
US8609347B2
(en)
|
2007-10-22 |
2013-12-17 |
The Regents Of The University Of California |
Biomarkers for prenatal diagnosis of congenital cytomegalovirus
|
BRPI0819193A2
(en)
*
|
2007-11-05 |
2017-05-23 |
Baltic Tech Dev Ltd |
use of modified base oligonucleotides in nucleic acid hybridization.
|
JP2011514881A
(en)
|
2007-11-09 |
2011-05-12 |
ザ ソルク インスティテュート フォー バイオロジカル スタディーズ |
Use of TAM receptor inhibitors as immunopotentiators and use of TAM activators as immunosuppressants
|
EP2222851B1
(en)
|
2007-11-20 |
2017-06-28 |
Ionis Pharmaceuticals, Inc. |
Modulation of cd40 expression
|
CA2910760C
(en)
|
2007-12-04 |
2019-07-09 |
Muthiah Manoharan |
Targeting lipids
|
JP5530933B2
(en)
|
2007-12-10 |
2014-06-25 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Compositions and methods for inhibiting factor VII gene expression
|
EP2224912B1
(en)
|
2008-01-02 |
2016-05-11 |
TEKMIRA Pharmaceuticals Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
EP2944649A1
(en)
|
2008-01-10 |
2015-11-18 |
Research Development Foundation |
Vaccines and diagnostics for the ehrlichioses
|
CA2712593A1
(en)
*
|
2008-02-01 |
2009-08-13 |
The Scripps Research Institute |
Methods for treating a condition characterized by dysfunction in protein homeostasis
|
WO2009100320A2
(en)
*
|
2008-02-07 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
AU2009222056A1
(en)
*
|
2008-03-01 |
2009-09-11 |
Abraxis Bioscience, Llc |
Treatment, diagnostic, and method for discovering antagonist using SPARC specific miRNAs
|
JP2011518117A
(en)
|
2008-03-05 |
2011-06-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
AU2009221778A1
(en)
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of California |
Molecular diagnosis and classification of malignant melanoma
|
CA2718904C
(en)
|
2008-03-17 |
2017-01-03 |
The Scripps Research Institute |
Combined chemical and genetic approaches for generation of induced pluripotent stem cells
|
US8426378B2
(en)
*
|
2008-03-21 |
2013-04-23 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucelosides and methods for their use
|
DK2285819T3
(en)
*
|
2008-04-04 |
2013-12-02 |
Isis Pharmaceuticals Inc |
OLIGOMER COMPOUNDS INCLUDING NEUTRAL BONDED, TERMINAL BICYCLIC NUCLEOSIDES
|
EP2274423A2
(en)
*
|
2008-04-04 |
2011-01-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
CA2721183C
(en)
|
2008-04-11 |
2019-07-16 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
EP2982753B1
(en)
|
2008-04-18 |
2018-06-06 |
Baxter International Inc. |
Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
|
US9884070B2
(en)
|
2008-04-21 |
2018-02-06 |
Lawrence Livermore National Security, Llc |
Selective high-affinity polydentate ligands and methods of making such
|
WO2009133971A1
(en)
*
|
2008-05-02 |
2009-11-05 |
Kyoto University |
Method of nuclear reprogramming
|
JP2011519951A
(en)
*
|
2008-05-07 |
2011-07-14 |
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー |
Enhancement of drug treatment by miRNA
|
US8258111B2
(en)
|
2008-05-08 |
2012-09-04 |
The Johns Hopkins University |
Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
|
WO2009149182A1
(en)
|
2008-06-04 |
2009-12-10 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small rna targeting of gene promoters
|
BRPI0916440A2
(en)
*
|
2008-07-15 |
2018-06-05 |
Hoffmann La Roche |
compositions and methods for inhibiting tgf-beta receptor gene expression
|
EP2317847B1
(en)
|
2008-07-29 |
2019-04-17 |
The Board of Regents of The University of Texas System |
Selective inhibition of polyglutamine protein expression
|
WO2010017248A2
(en)
|
2008-08-04 |
2010-02-11 |
University Of Miami |
Sting (stimulator of interferon genes), a regulator of innate immune responses
|
WO2010017509A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression for the treatment of cns related disorders
|
EP3375451A1
(en)
|
2008-08-25 |
2018-09-19 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to ctgf
|
EP3081648A1
(en)
|
2008-08-25 |
2016-10-19 |
Excaliard Pharmaceuticals, Inc. |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
WO2010028054A1
(en)
|
2008-09-02 |
2010-03-11 |
Alnylam Europe Ag. |
Compositions and methods for inhibiting expression of mutant egfr gene
|
CA2738019A1
(en)
|
2008-09-23 |
2010-04-08 |
President And Fellows Of Harvard College |
Sirt4 and uses thereof
|
JP2012513953A
(en)
|
2008-09-23 |
2012-06-21 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
Chemical modification of monomers and oligonucleotides using cycloaddition
|
US8501805B2
(en)
*
|
2008-09-24 |
2013-08-06 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-L-bicyclic nucleosides
|
EP2361256B1
(en)
*
|
2008-09-24 |
2013-04-10 |
Isis Pharmaceuticals, Inc. |
Cyclohexenyl nucleic acid analogs
|
EP2334793B1
(en)
|
2008-09-25 |
2016-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of serum amyloid a gene
|
JP6128732B2
(en)
*
|
2008-10-03 |
2017-05-17 |
クルナ・インコーポレーテッド |
Treatment of apolipoprotein-A1 related diseases by suppression of natural antisense transcripts against apolipoprotein-A1
|
WO2010042669A2
(en)
|
2008-10-07 |
2010-04-15 |
Ipierian, Inc. |
Co-culture compositions and methods
|
WO2010042877A1
(en)
|
2008-10-09 |
2010-04-15 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
AU2009305636A1
(en)
|
2008-10-15 |
2010-04-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of Factor 11 expression
|
EA029762B1
(en)
|
2008-10-20 |
2018-05-31 |
Элнилэм Фармасьютикалз, Инк. |
Compositions and methods for inhibiting expression of transthyretin
|
EP2447274B1
(en)
|
2008-10-24 |
2017-10-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
AU2009308217B2
(en)
|
2008-10-24 |
2016-01-21 |
Ionis Pharmaceuticals, Inc. |
5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
|
WO2010054189A1
(en)
|
2008-11-06 |
2010-05-14 |
University Of Miami |
Role of soluble upar in the pathogenesis of proteinuric kidney disease
|
KR20220150995A
(en)
|
2008-11-10 |
2022-11-11 |
알닐람 파마슈티칼스 인코포레이티드 |
Novel lipids and compositions for the delivery of therapeutics
|
US8735082B2
(en)
|
2008-11-10 |
2014-05-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Gene signature for predicting prognosis of patients with solid tumors
|
CA2743249A1
(en)
*
|
2008-11-17 |
2010-05-20 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of factor vii genes
|
DK2365803T3
(en)
*
|
2008-11-24 |
2018-01-22 |
Univ Northwestern |
POLYVALENT RNA NANOPARTICLE COMPOSITIONS
|
ES2779001T3
(en)
|
2008-12-03 |
2020-08-13 |
Scripps Research Inst |
Stem cell cultures
|
ES2637063T3
(en)
|
2008-12-04 |
2017-10-10 |
Curna, Inc. |
Treatment of diseases related to tumor suppressor genes by inhibiting the natural antisense transcript to the gene
|
JP5971948B2
(en)
*
|
2008-12-04 |
2016-08-17 |
クルナ・インコーポレーテッド |
Treatment of vascular endothelial growth factor (VEGF) -related diseases by suppression of natural antisense transcripts against VEGF
|
WO2010065792A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
|
MX366774B
(en)
|
2008-12-04 |
2019-07-24 |
Curna Inc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1.
|
WO2010068816A1
(en)
|
2008-12-10 |
2010-06-17 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
US20100233172A1
(en)
*
|
2008-12-16 |
2010-09-16 |
Bristol-Myers Squibb Company |
Methods of inhibiting quiescent tumor proliferation
|
BRPI0922572A2
(en)
|
2008-12-17 |
2019-09-24 |
Scripps Research Inst |
method for culturing pluripotent cells, pluripotent mammalian cell culture, cell culture medium, isolated pluripotent animal cell, and method for increasing pluripotence of a mammalian cell.
|
US20100184844A1
(en)
*
|
2009-01-08 |
2010-07-22 |
Northwestern University |
Inhibition of Bacterial Protein Production by Polyvalent Oligonucleotide Modified Nanoparticle Conjugates
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
KR101546673B1
(en)
*
|
2009-01-15 |
2015-08-25 |
삼성전자주식회사 |
Toner for electrophotographic and process for preparing the same
|
CA2751342C
(en)
|
2009-01-29 |
2019-05-07 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
|
MX2011007776A
(en)
*
|
2009-02-03 |
2011-08-12 |
Hoffmann La Roche |
Compositions and methods for inhibiting expression of ptp1b genes.
|
WO2010090969A1
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
EP2393825A2
(en)
|
2009-02-06 |
2011-12-14 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
PL2396038T3
(en)
|
2009-02-12 |
2016-05-31 |
Curna Inc |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
US20110319476A1
(en)
|
2009-02-12 |
2011-12-29 |
Opko Curna, Llc |
Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
US8975389B2
(en)
|
2009-03-02 |
2015-03-10 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
EP2403946A4
(en)
|
2009-03-04 |
2012-11-14 |
|
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
|
JP6032724B2
(en)
|
2009-03-12 |
2016-11-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Lipid preparation composition and method for inhibiting expression of Eg5 gene and VEGF gene
|
US9464287B2
(en)
|
2009-03-16 |
2016-10-11 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
|
CA2755404C
(en)
|
2009-03-17 |
2020-03-24 |
Joseph Collard |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
US20100240065A1
(en)
*
|
2009-03-18 |
2010-09-23 |
Boehringer Ingelheim International Gmbh |
Prolyl Hydroxylase Compositions and Methods of Use Thereof
|
US20100240069A1
(en)
*
|
2009-03-18 |
2010-09-23 |
Boehringer Ingelheim International Gmbh |
Drug Discovery Assay for Modulators of HIF-Prolyl Hydroxylase Activity
|
US20110045080A1
(en)
*
|
2009-03-24 |
2011-02-24 |
William Marsh Rice University |
Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
|
WO2010126670A2
(en)
|
2009-03-27 |
2010-11-04 |
Gojo Industries, Inc. |
Compositions and methods for screening and using compounds antagonizing spore-surface interactions
|
JP6145270B2
(en)
|
2009-04-15 |
2017-06-07 |
ノースウェスタン ユニバーシティ |
Delivery of oligonucleotide functionalized nanoparticles
|
EP3248618A1
(en)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Innate immune suppression enables repeated delivery of long rna molecules
|
EP2421972A2
(en)
|
2009-04-24 |
2012-02-29 |
The Board of Regents of The University of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
|
US8318690B2
(en)
|
2009-05-01 |
2012-11-27 |
Curna, Inc. |
Treatment of hemoglobin (HBF/HBG) related diseases by inhibition of natural antisense transcript to HBF/HBG
|
SG10201402054UA
(en)
|
2009-05-05 |
2014-09-26 |
Muthiah Manoharan |
Lipid compositions
|
AU2010245933B2
(en)
|
2009-05-05 |
2016-06-16 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
CN106237345A
(en)
|
2009-05-06 |
2016-12-21 |
库尔纳公司 |
By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
|
ES2609655T3
(en)
|
2009-05-06 |
2017-04-21 |
Curna, Inc. |
Treatment of diseases related to tristetraproline (TTP) by inhibition of natural antisense transcript for TTP
|
ES2618572T3
(en)
|
2009-05-08 |
2017-06-21 |
Curna, Inc. |
Treatment of diseases related to the dystrophin family by inhibiting a natural antisense transcript for the dmd family
|
WO2010130771A2
(en)
*
|
2009-05-15 |
2010-11-18 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes
|
US20120107331A1
(en)
|
2009-05-15 |
2012-05-03 |
Yale University |
Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
|
JP5922017B2
(en)
|
2009-05-18 |
2016-05-24 |
クルナ・インコーポレーテッド |
Treatment of reprogramming factor-related diseases by suppression of natural antisense transcripts against the reprogramming factor
|
WO2010135695A2
(en)
|
2009-05-22 |
2010-11-25 |
Curna, Inc. |
TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
|
EP2435571B1
(en)
|
2009-05-28 |
2016-12-14 |
CuRNA, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
CN104873464B
(en)
|
2009-06-10 |
2018-06-22 |
阿布特斯生物制药公司 |
Improved lipid formulations
|
ES2629339T3
(en)
|
2009-06-16 |
2017-08-08 |
Curna, Inc. |
Treatment of diseases related to paraoxonase 1 (pon1) by inhibition of natural antisense transcript to pon1
|
KR101801404B1
(en)
|
2009-06-16 |
2017-12-20 |
큐알엔에이, 인크. |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
NZ624712A
(en)
|
2009-06-17 |
2015-10-30 |
Isis Pharmaceuticals Inc |
Compositions and methods for modulation of smn2 splicing in a subject
|
CA2765889A1
(en)
|
2009-06-24 |
2010-12-29 |
Opko Curna, Llc |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
KR101807324B1
(en)
|
2009-06-26 |
2017-12-08 |
큐알엔에이, 인크. |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
WO2011011366A2
(en)
*
|
2009-07-20 |
2011-01-27 |
Constellation Pharmaceuticals |
Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
|
WO2011011775A1
(en)
|
2009-07-24 |
2011-01-27 |
The Regents Of The University Of California |
Methods and compositions for treating and preventing disease associated with avb5 integrin
|
CN102712925B
(en)
|
2009-07-24 |
2017-10-27 |
库尔纳公司 |
It is diseases related that SIRTUIN (SIRT) is treated by suppressing SIRTUIN (SIRT) natural antisense transcript
|
CA2769665A1
(en)
|
2009-08-05 |
2011-02-10 |
Opko Curna, Llc |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
EP2462153B1
(en)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
EP2464731B1
(en)
|
2009-08-11 |
2016-10-05 |
CuRNA, Inc. |
Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
|
AP2015008874A0
(en)
|
2009-08-14 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
EP2464976B1
(en)
|
2009-08-14 |
2018-11-21 |
The Regents of The University of California |
Methods of diagnosing and treating autism
|
WO2011022420A1
(en)
|
2009-08-17 |
2011-02-24 |
Yale University |
Methylation biomarkers and methods of use
|
US20120148604A1
(en)
|
2009-08-20 |
2012-06-14 |
Transposagen Biopharmaceuticals, Inc. |
Trp inhibitors and uses thereof
|
WO2011022606A2
(en)
|
2009-08-21 |
2011-02-24 |
Curna, Inc. |
Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
|
KR101892760B1
(en)
|
2009-08-25 |
2018-08-28 |
큐알엔에이, 인크. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
DK2473522T3
(en)
|
2009-09-02 |
2016-11-28 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
CN102791861B
(en)
|
2009-09-25 |
2018-08-07 |
库尔纳公司 |
FLG relevant diseases are treated by adjusting expression and the activity of Filaggrin (FLG)
|
US8394948B2
(en)
*
|
2009-09-30 |
2013-03-12 |
Glen Research Corporation |
Reagents utilizing a serinol scaffold for labeling synthetic oligonucleotides
|
RU2539772C2
(en)
|
2009-10-22 |
2015-01-27 |
Дженентек, Инк. |
Methods and compositions for hepsin modulation of macrophage-stimulating protein
|
EP2494066B1
(en)
|
2009-10-27 |
2017-04-05 |
Swift Biosciences, Inc. |
Bimolecular primers
|
AU2010313154B2
(en)
|
2009-10-30 |
2016-05-12 |
Northwestern University |
Templated nanoconjugates
|
US20110110860A1
(en)
|
2009-11-02 |
2011-05-12 |
The Board Of Regents Of The University Of Texas System |
Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
|
KR20120102674A
(en)
|
2009-11-03 |
2012-09-18 |
유니버시티 오브 버지니아 페이턴트 파운데이션 |
Versatile, visible method for detecting polymeric analytes
|
DK2496594T3
(en)
|
2009-11-06 |
2018-03-05 |
The J David Gladstone Inst |
METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS
|
WO2011054939A2
(en)
|
2009-11-09 |
2011-05-12 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of kif10 genes
|
AU2010321885B2
(en)
|
2009-11-20 |
2015-12-24 |
The Regents Of The University Of California |
Epithelial membrane protein-2 (EMP2) and proliferative vitreoretinopathy (PVR)
|
EP2504450B1
(en)
|
2009-11-23 |
2016-07-06 |
Swift Biosciences, Inc. |
Devices to extend single stranded target molecules
|
PE20121584A1
(en)
|
2009-11-30 |
2012-11-29 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
|
CA3044884A1
(en)
|
2009-12-07 |
2011-06-16 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
ES2661813T3
(en)
|
2009-12-16 |
2018-04-04 |
Curna, Inc. |
Treatment of diseases related to membrane transcription factor peptidase, site 1 (mbtps1) by inhibition of the natural antisense transcript to the mbtps1 gene
|
US20130017223A1
(en)
|
2009-12-18 |
2013-01-17 |
The University Of British Columbia |
Methods and compositions for delivery of nucleic acids
|
US20110152349A1
(en)
|
2009-12-18 |
2011-06-23 |
Anke Geick |
Compositions and methods for inhibiting expression of il-18 genes
|
EP2515947B1
(en)
|
2009-12-23 |
2021-10-06 |
CuRNA, Inc. |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
WO2011079261A2
(en)
|
2009-12-23 |
2011-06-30 |
Curna, Inc. |
Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
|
RU2615450C2
(en)
|
2009-12-29 |
2017-04-04 |
Курна, Инк. |
Treating diseases associated with nuclear respiratory factor 1 (nrf1) by inhibition of natural antisense transcript to nrf1
|
JP5982288B2
(en)
|
2009-12-29 |
2016-08-31 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of tumor protein 63-related diseases by inhibition of natural antisense transcripts against tumor protein 63 (p63)
|
EP2519632B1
(en)
|
2009-12-31 |
2018-04-11 |
CuRNA, Inc. |
Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
|
DK2521784T3
(en)
|
2010-01-04 |
2018-03-12 |
Curna Inc |
TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
|
JP5963680B2
(en)
|
2010-01-06 |
2016-08-03 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of pancreatic developmental gene diseases by inhibition of natural antisense transcripts against pancreatic developmental genes
|
US8779118B2
(en)
|
2010-01-11 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2011085347A2
(en)
|
2010-01-11 |
2011-07-14 |
Opko Curna, Llc |
Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
|
EP2524042A2
(en)
|
2010-01-12 |
2012-11-21 |
Yale University |
Structured rna motifs and compounds and methods for their use
|
WO2011088391A2
(en)
*
|
2010-01-14 |
2011-07-21 |
Haplomics, Inc. |
Predicting and reducing alloimmunogenicity of protein therapeutics
|
ES2671877T3
(en)
|
2010-01-25 |
2018-06-11 |
Curna, Inc. |
Treatment of diseases related to RNASA (H1) by inhibition of the natural antisense transcript to RNASA H1
|
US9216189B2
(en)
|
2010-01-25 |
2015-12-22 |
Icahn School Of Medicine At Mount Sinai |
Antibodies which bind type I cannabinoid receptor/angiotensis II receptor heteromers
|
US9198972B2
(en)
|
2010-01-28 |
2015-12-01 |
Alnylam Pharmaceuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
WO2011094759A2
(en)
|
2010-02-01 |
2011-08-04 |
The Regents Of The University Of California |
Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
|
WO2011097388A1
(en)
|
2010-02-03 |
2011-08-11 |
Alnylam Pharmaceuticals, Inc. |
Selective inhibition of polyglutamine protein expression
|
CA2824843A1
(en)
|
2010-02-04 |
2011-08-11 |
Ico Therapeutics Inc. |
Dosing regimens for treating and preventing ocular disorders using c-raf antisense
|
TW201129365A
(en)
|
2010-02-05 |
2011-09-01 |
Hoffmann La Roche |
Compositions and methods for inhibiting expression of IKK2 genes
|
CN102844435B
(en)
|
2010-02-22 |
2017-05-10 |
库尔纳公司 |
Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
|
KR20130004579A
(en)
|
2010-02-23 |
2013-01-11 |
제넨테크, 인크. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
WO2011108930A1
(en)
|
2010-03-04 |
2011-09-09 |
Interna Technologies Bv |
A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
US20130101512A1
(en)
|
2010-03-12 |
2013-04-25 |
Chad A. Mirkin |
Crosslinked polynucleotide structure
|
US9193752B2
(en)
|
2010-03-17 |
2015-11-24 |
Isis Pharmaceuticals, Inc. |
5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US8889350B2
(en)
|
2010-03-26 |
2014-11-18 |
Swift Biosciences, Inc. |
Methods and compositions for isolating polynucleotides
|
AU2011235276B2
(en)
|
2010-03-29 |
2015-09-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
RU2612884C2
(en)
|
2010-04-02 |
2017-03-13 |
Курна, Инк. |
Treatment of diseases associated with colonystimulating factor 3 (csf3) by inhibition of natural antisense transcript to csf3
|
EP2556160A4
(en)
|
2010-04-09 |
2013-08-21 |
Curna Inc |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
WO2011133695A2
(en)
|
2010-04-20 |
2011-10-27 |
Swift Biosciences, Inc. |
Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
|
WO2011133868A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
US10913767B2
(en)
|
2010-04-22 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
EP2625186B1
(en)
|
2010-04-28 |
2016-07-27 |
Ionis Pharmaceuticals, Inc. |
5' modified nucleosides and oligomeric compounds prepared therefrom
|
JP5988961B2
(en)
|
2010-04-28 |
2016-09-07 |
ザ ジェイ. デヴィッド グラッドストーン インスティテューツ |
Methods for generating cardiomyocytes
|
CN103154014B
(en)
|
2010-04-28 |
2015-03-25 |
Isis制药公司 |
Modified nucleosides, modified nucleosides-like and oligomeric compounds prepared therefrom
|
ES2625689T3
(en)
|
2010-04-29 |
2017-07-20 |
Ionis Pharmaceuticals, Inc. |
Modulation of transthyretin expression
|
CN107090045A
(en)
|
2010-05-03 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
Composition and method for tumor diagnosis and therapy
|
WO2011139387A1
(en)
|
2010-05-03 |
2011-11-10 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
TWI586356B
(en)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
|
EP2576808B1
(en)
|
2010-05-24 |
2017-10-25 |
Koch Biological Solutions, LLC |
Novel reporter constructs for compound screening
|
EP2576784B1
(en)
|
2010-05-26 |
2017-11-15 |
CuRNA, Inc. |
Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
|
KR20180053419A
(en)
|
2010-05-26 |
2018-05-21 |
큐알엔에이, 인크. |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
WO2011150226A1
(en)
|
2010-05-26 |
2011-12-01 |
Landers James P |
Method for detecting nucleic acids based on aggregate formation
|
EP2576579B1
(en)
|
2010-06-02 |
2018-08-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
US8957200B2
(en)
|
2010-06-07 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US9476101B2
(en)
|
2010-06-07 |
2016-10-25 |
Firefly Bioworks, Inc. |
Scanning multifunctional particles
|
US8846637B2
(en)
|
2010-06-08 |
2014-09-30 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US9638632B2
(en)
|
2010-06-11 |
2017-05-02 |
Vanderbilt University |
Multiplexed interferometric detection system and method
|
WO2011163499A2
(en)
|
2010-06-23 |
2011-12-29 |
Opko Curna, Llc |
Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
|
US9168297B2
(en)
|
2010-06-23 |
2015-10-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Regulation of skin pigmentation by neuregulin-1 (NRG-1)
|
CA2804599C
(en)
|
2010-07-06 |
2023-01-31 |
Interna Technologies Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
WO2012009402A2
(en)
|
2010-07-14 |
2012-01-19 |
Opko Curna Llc |
Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
|
DK3031920T3
(en)
|
2010-07-19 |
2019-10-14 |
Ionis Pharmaceuticals Inc |
MODULATION OF DYSTROPHY MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012021554A1
(en)
|
2010-08-09 |
2012-02-16 |
Yale University |
Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
|
AU2011312205B2
(en)
|
2010-10-05 |
2015-08-13 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
CA2813901C
(en)
|
2010-10-06 |
2019-11-12 |
Curna, Inc. |
Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
|
EP2630240A1
(en)
|
2010-10-18 |
2013-08-28 |
Arrowhead Research Corporation |
Compositions and methods for inhibiting expression of rrm2 genes
|
WO2012052391A1
(en)
|
2010-10-19 |
2012-04-26 |
Glaxo Group Limited |
Polypeptide with jmjd3 catalytic activity
|
EP2630241B1
(en)
|
2010-10-22 |
2018-10-17 |
CuRNA, Inc. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
ES2677070T3
(en)
|
2010-10-27 |
2018-07-27 |
Curna, Inc. |
Treatment of diseases related to the developmental regulator 1 associated with interferon (ifrd1) by inhibition of the natural antisense transcript to the ifrd1 gene
|
CN110123830A
(en)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare
|
EP2640853B1
(en)
|
2010-11-17 |
2018-12-26 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
EP2643484A4
(en)
|
2010-11-22 |
2014-04-16 |
Univ California |
Methods of identifying a cellular nascent rna transcript
|
ES2657590T3
(en)
|
2010-11-23 |
2018-03-06 |
Curna, Inc. |
Treatment of nanog related diseases by inhibiting the natural antisense transcript to nanog
|
US9150926B2
(en)
|
2010-12-06 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diagnosis and treatment of adrenocortical tumors using human microRNA-483
|
WO2012078967A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (epo) production
|
EP2648763A4
(en)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
AU2011349446C1
(en)
|
2010-12-22 |
2016-01-21 |
Fate Therapauetics, Inc. |
Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
|
WO2012099755A1
(en)
|
2011-01-11 |
2012-07-26 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
US20130338178A1
(en)
|
2011-02-02 |
2013-12-19 |
The Trustees Of Princeton University |
Sirtuin modulators as inhibitors of cytomegalovirus
|
TWI593416B
(en)
|
2011-02-02 |
2017-08-01 |
艾克厘德製藥公司 |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
|
AU2012212105A1
(en)
|
2011-02-03 |
2013-09-12 |
Mirna Therapeutics, Inc. |
Synthetic mimics of miR-124
|
MY165507A
(en)
|
2011-02-03 |
2018-03-28 |
Mirna Therapeutics Inc |
Synthetic mimics of mir-34
|
US10017764B2
(en)
|
2011-02-08 |
2018-07-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
DK2675474T3
(en)
|
2011-02-15 |
2019-04-23 |
Vaxiion Therapeutics Llc |
THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES
|
ES2716865T3
(en)
|
2011-02-18 |
2019-06-17 |
Scripps Research Inst |
Directed differentiation of oligodendrocyte precursor cells to a myelinating cell target
|
US9562853B2
(en)
|
2011-02-22 |
2017-02-07 |
Vanderbilt University |
Nonaqueous backscattering interferometric methods
|
WO2012119989A2
(en)
|
2011-03-04 |
2012-09-13 |
Oryzon Genomics, S.A. |
Methods and antibodies for the diagnosis and treatment of cancer
|
JP6108628B2
(en)
|
2011-03-29 |
2017-04-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Composition and method for inhibiting expression of TMPRSS6 gene
|
EP2694660B1
(en)
|
2011-04-03 |
2018-08-08 |
The General Hospital Corporation |
Efficient protein expression in vivo using modified rna (mod-rna)
|
US20120301904A1
(en)
|
2011-04-26 |
2012-11-29 |
Prosetta Antiviral, Inc |
Multiprotein assemblies
|
US20140186844A1
(en)
|
2011-04-26 |
2014-07-03 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
WO2012151289A2
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system to detect aggregate formation on a substrate
|
WO2012151268A1
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system for high throughput optical and label free detection of analytes
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
RU2620980C2
(en)
|
2011-06-09 |
2017-05-30 |
Курна, Инк. |
Treatment of diseases associated with frataxin (fxn), by inhibiting natural antisense fxn transcript
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
AU2012267546B2
(en)
|
2011-06-10 |
2015-12-24 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (KLKB1) expression
|
CN103890000B
(en)
|
2011-06-21 |
2017-09-01 |
阿尔尼拉姆医药品有限公司 |
(ANGPTL3) the iRNA compositions of angiopoietin-like 3 and its application method
|
EP3388068A1
(en)
|
2011-06-21 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
Composition and methods for inhibition of expression of protein c (proc) genes
|
RU2631805C2
(en)
|
2011-06-21 |
2017-09-26 |
Элнилэм Фармасьютикалз, Инк. |
Compositions and methods for apolipoprotein c-iii (apoc3) gene expression inhibition
|
EP3366312A1
(en)
|
2011-06-23 |
2018-08-29 |
Alnylam Pharmaceuticals, Inc. |
Serpina 1 sirnas: compositions of matter and methods of treatment
|
US9322021B2
(en)
|
2011-06-29 |
2016-04-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (KLKB1) expression
|
TW202244278A
(en)
|
2011-06-30 |
2022-11-16 |
美商艾羅海德製藥公司 |
Compositions and methods for inhibiting gene expression of hepatitis b virus
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
DK2738255T3
(en)
|
2011-07-29 |
2017-03-06 |
Univ Tokushima |
ERAP1-Derived Peptide and its Use
|
US20140328811A1
(en)
|
2011-08-01 |
2014-11-06 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
US10202599B2
(en)
|
2011-08-11 |
2019-02-12 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
US10583128B2
(en)
|
2011-09-06 |
2020-03-10 |
Curna, Inc. |
Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules
|
US9644241B2
(en)
|
2011-09-13 |
2017-05-09 |
Interpace Diagnostics, Llc |
Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
|
CA2847698C
(en)
|
2011-09-14 |
2020-09-01 |
Northwestern University |
Nanoconjugates able to cross the blood-brain barrier
|
WO2013040548A2
(en)
|
2011-09-17 |
2013-03-21 |
Yale University |
Fluoride-responsive riboswitchs, fluoride transporters, and methods of use
|
WO2013049328A1
(en)
|
2011-09-27 |
2013-04-04 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
WO2013063519A1
(en)
|
2011-10-26 |
2013-05-02 |
Asuragen, Inc. |
Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
|
DK2790736T3
(en)
|
2011-12-12 |
2018-05-07 |
Oncoimmunin Inc |
In vivo delivery of oligonucleotides
|
LT2790687T
(en)
|
2011-12-16 |
2018-12-10 |
Poseida Therapeutics, Inc. |
Trpc4 modulators for use in the treatment or prevention of pain
|
RS63244B1
(en)
|
2011-12-16 |
2022-06-30 |
Modernatx Inc |
Modified mrna compositions
|
EP2794881B1
(en)
|
2011-12-22 |
2018-06-27 |
InteRNA Technologies B.V. |
Mirna for treating head and neck cancer
|
WO2013096837A1
(en)
|
2011-12-22 |
2013-06-27 |
Isis Pharmaceuticals, Inc. |
Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression
|
WO2013106358A1
(en)
|
2012-01-10 |
2013-07-18 |
Hussain M Mahmood |
Method of treating hyperlipidemia and atherosclerosis with mir-30c
|
EP3330278A1
(en)
|
2012-02-08 |
2018-06-06 |
Ionis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
CN104302304A
(en)
|
2012-02-16 |
2015-01-21 |
宾西法利亚州研究基金会 |
Modulators of acyl-coa lysocardiolipin acyltransferase 1 (ALCAT1) and uses thereof
|
SG11201405669XA
(en)
|
2012-03-13 |
2014-10-30 |
Swift Biosciences Inc |
Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
|
US10105351B2
(en)
|
2012-03-14 |
2018-10-23 |
University Of Central Florida Research Foundation, Inc. |
Neurofibromatoses therapeutic agents and screening for same
|
US20150031750A1
(en)
|
2012-03-15 |
2015-01-29 |
The Scripps Research Institute |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
US9610362B2
(en)
|
2012-03-16 |
2017-04-04 |
Valerion Therapeutics, Llc |
Antisense conjugates for decreasing expression of DMPK
|
US9340784B2
(en)
|
2012-03-19 |
2016-05-17 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating alpha-1-antitrypsin expression
|
CN108949772A
(en)
|
2012-04-02 |
2018-12-07 |
现代泰克斯公司 |
For generating the modification polynucleotides of biological agent relevant to human diseases and protein
|
EP2833892A4
(en)
|
2012-04-02 |
2016-07-20 |
Moderna Therapeutics Inc |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
US9612235B2
(en)
|
2012-04-05 |
2017-04-04 |
Koch Biological Solutions, Llc |
Herbicidal compound screening
|
EP2850092B1
(en)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
WO2013159108A2
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
US20160054299A9
(en)
|
2012-04-24 |
2016-02-25 |
University Of Miami |
Perforin 2 defense against invasive and multidrug resistant pathogens
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
US9273949B2
(en)
|
2012-05-11 |
2016-03-01 |
Vanderbilt University |
Backscattering interferometric methods
|
WO2013177248A2
(en)
|
2012-05-22 |
2013-11-28 |
Isis Pharmaceuticals, Inc. |
Modulation of enhancer rna mediated gene expression
|
EP2855425A4
(en)
|
2012-06-04 |
2016-05-18 |
Scripps Research Inst |
Novel phenyl glyoxal probes
|
PT3461895T
(en)
|
2012-06-25 |
2020-09-08 |
Baylor College Medicine |
Modulation of ube3a-ats expression
|
US20140038182A1
(en)
|
2012-07-17 |
2014-02-06 |
Dna Logix, Inc. |
Cooperative primers, probes, and applications thereof
|
US20150164800A1
(en)
|
2012-07-25 |
2015-06-18 |
Xetrios Therapeutics, Inc. |
Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine
|
WO2014018930A1
(en)
|
2012-07-27 |
2014-01-30 |
Isis Pharmaceuticals. Inc. |
Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
|
EP2885312A4
(en)
|
2012-08-15 |
2016-01-20 |
Isis Pharmaceuticals Inc |
Method of preparing oligomeric compounds using modified capping protocols
|
WO2014036528A2
(en)
|
2012-08-31 |
2014-03-06 |
Ixchel Pharma, Llc |
Agents useful for treating obesity, diabetes and related disorders
|
WO2014045126A2
(en)
|
2012-09-18 |
2014-03-27 |
Uti Limited Partnership |
Treatment of pain by inhibition of usp5 de-ubiquitinase
|
US20140100124A1
(en)
|
2012-10-04 |
2014-04-10 |
Asuragen, Inc. |
Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
|
AU2013204200B2
(en)
|
2012-10-11 |
2016-10-20 |
Brandeis University |
Treatment of amyotrophic lateral sclerosis
|
EP4052709A1
(en)
|
2012-10-11 |
2022-09-07 |
Ionis Pharmaceuticals, Inc. |
Methods of treating kennedy's disease
|
US9175291B2
(en)
|
2012-10-11 |
2015-11-03 |
Isis Pharmaceuticals Inc. |
Modulation of androgen receptor expression
|
EP2906699A4
(en)
|
2012-10-11 |
2016-06-08 |
Ionis Pharmaceuticals Inc |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2912194B1
(en)
|
2012-10-26 |
2019-05-08 |
Memorial Sloan-Kettering Cancer Center |
Androgen receptor variants and methods for making and using
|
EP2912179A4
(en)
|
2012-10-26 |
2016-10-12 |
Geron Corp |
C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
|
US20140120116A1
(en)
|
2012-10-26 |
2014-05-01 |
The Chinese University Of Hong Kong |
Treatment of cancer using smad3 inhibitor
|
EP2914621B1
(en)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
WO2014072357A1
(en)
|
2012-11-06 |
2014-05-15 |
Interna Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
|
ES2921623T3
(en)
|
2012-11-26 |
2022-08-30 |
Modernatx Inc |
terminally modified RNA
|
BR112015013311A2
(en)
|
2012-12-07 |
2017-11-14 |
Haplomics Inc |
tolerance induction and factor 8 mutation repair
|
WO2014113089A2
(en)
|
2013-01-17 |
2014-07-24 |
Moderna Therapeutics, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
CA2898326C
(en)
|
2013-01-18 |
2022-05-17 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
DK2951191T3
(en)
|
2013-01-31 |
2019-01-14 |
Ionis Pharmaceuticals Inc |
PROCEDURE FOR MANUFACTURING OLIGOMERIC COMPOUNDS USING MODIFIED CLUTCH PROTOCOLS
|
US20140288097A1
(en)
|
2013-02-07 |
2014-09-25 |
The Regents Of The University Of California |
Use of translational profiling to identify target molecules for therapeutic treatment
|
US9593333B2
(en)
|
2013-02-14 |
2017-03-14 |
Ionis Pharmaceuticals, Inc. |
Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations
|
US20150366890A1
(en)
|
2013-02-25 |
2015-12-24 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
US10398661B2
(en)
|
2013-02-28 |
2019-09-03 |
The Board Of Regents Of The University Of Texas System |
Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers
|
WO2014159813A1
(en)
|
2013-03-13 |
2014-10-02 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
HUE034987T2
(en)
|
2013-03-14 |
2018-05-02 |
Alnylam Pharmaceuticals Inc |
Complement component c5 irna compositions and methods of use thereof
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP4163387A1
(en)
|
2013-03-15 |
2023-04-12 |
The University of Chicago |
Methods and compositions related to t-cell activity
|
WO2014144844A1
(en)
|
2013-03-15 |
2014-09-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
|
CA2918194C
(en)
|
2013-03-27 |
2022-12-06 |
The General Hospital Corporation |
Methods and agents for treating alzheimer's disease
|
EP2981617B1
(en)
|
2013-04-04 |
2023-07-05 |
President and Fellows of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
WO2014172698A1
(en)
|
2013-04-19 |
2014-10-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
US20160083698A1
(en)
|
2013-04-19 |
2016-03-24 |
The Regents Of The University Of California |
Lone star virus
|
EA031393B1
(en)
|
2013-05-01 |
2018-12-28 |
Ионис Фармасьютикалз, Инк. |
Compositions and methods for modulating hbv and ttr expression
|
PT2999785T
(en)
|
2013-05-22 |
2018-07-09 |
Alnylam Pharmaceuticals Inc |
Serpina1 irna compositions and methods of use thereof
|
BR112015029276B1
(en)
|
2013-05-22 |
2022-07-12 |
Alnylam Pharmaceuticals, Inc |
DUAL STRIP IRNA AGENT CAPABLE OF INHIBITING THE EXPRESSION OF TMPRSS6, PHARMACEUTICAL COMPOSITION AND USE THEREOF
|
EP3004396B1
(en)
|
2013-06-06 |
2019-10-16 |
The General Hospital Corporation |
Compositions for the treatment of cancer
|
US20160129089A1
(en)
|
2013-06-13 |
2016-05-12 |
Antisense Therapeutics Ltd |
Combination therapy
|
EP3656386A1
(en)
|
2013-06-21 |
2020-05-27 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
|
WO2015002971A2
(en)
|
2013-07-02 |
2015-01-08 |
Isis Pharmaceuticals, Inc. |
Modulators of growth hormone receptor
|
HRP20211563T1
(en)
|
2013-07-11 |
2022-01-07 |
Modernatx, Inc. |
Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
|
JP6697384B2
(en)
|
2013-07-25 |
2020-05-20 |
イグジキュア, インコーポレーテッドExicure, Inc. |
Spherical nucleic acid-based constructs as immunostimulants for prophylactic and therapeutic use
|
AU2014306271A1
(en)
|
2013-08-08 |
2016-03-24 |
The Scripps Research Institute |
A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
|
TW201536329A
(en)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
|
NZ716816A
(en)
|
2013-08-28 |
2022-05-27 |
Ionis Pharmaceuticals Inc |
Modulation of prekallikrein (pkk) expression
|
CA2923029A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
EP3043827B1
(en)
|
2013-09-13 |
2019-07-03 |
Ionis Pharmaceuticals, Inc. |
Modulators of complement factor b
|
EP3052626A1
(en)
|
2013-10-02 |
2016-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
AU2014329452B2
(en)
|
2013-10-03 |
2019-06-20 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
AU2014329560B2
(en)
|
2013-10-04 |
2017-03-02 |
Novartis Ag |
3'end caps for RNAi agents for use in RNA interference
|
WO2015051366A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Novel formats for organic compounds for use in rna interference
|
EP3052107B1
(en)
|
2013-10-04 |
2018-05-02 |
Novartis AG |
Organic compounds to treat hepatitis b virus
|
UA124961C2
(en)
|
2013-10-04 |
2021-12-22 |
Елнілем Фармасьютикалз, Інк. |
Compositions and methods for inhibiting expression of the alas1 gene
|
WO2015054451A1
(en)
|
2013-10-09 |
2015-04-16 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
US9644037B2
(en)
|
2013-10-18 |
2017-05-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use
|
WO2015061091A1
(en)
|
2013-10-21 |
2015-04-30 |
The General Hospital Corporation |
Methods relating to circulating tumor cell clusters and the treatment of cancer
|
WO2015061246A1
(en)
|
2013-10-21 |
2015-04-30 |
Isis Pharmaceuticals, Inc. |
Method for solution phase detritylation of oligomeric compounds
|
US10301622B2
(en)
|
2013-11-04 |
2019-05-28 |
Northwestern University |
Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
|
CA2929555A1
(en)
|
2013-11-08 |
2015-05-14 |
Baylor Research Institute |
Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure
|
CA2932122C
(en)
|
2013-12-03 |
2022-04-19 |
Northwestern University |
Liposomal particles, methods of making same and uses thereof
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
WO2015085183A2
(en)
|
2013-12-06 |
2015-06-11 |
Swift Biosciences, Inc. |
Cleavable competitor polynucleotides
|
EP3080122B1
(en)
|
2013-12-11 |
2018-10-31 |
Biogen MA Inc. |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
WO2015089338A2
(en)
|
2013-12-11 |
2015-06-18 |
Sloan-Kettering Institute For Cancer Research |
Glucocorticoid inhibitors for treatment of prostate cancer
|
IL282401B
(en)
|
2013-12-12 |
2022-08-01 |
Alnylam Pharmaceuticals Inc |
Complement component irna compositions and methods of use thereof
|
US10900083B2
(en)
|
2013-12-20 |
2021-01-26 |
The General Hospital Corporation |
Methods and assays relating to circulating tumor cells
|
KR102198082B1
(en)
|
2013-12-24 |
2021-01-05 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Modulation of angiopoietin-like 3 expression
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP3960860A3
(en)
|
2014-02-11 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
US10087444B2
(en)
|
2014-02-13 |
2018-10-02 |
The Board Of Regents Of The University Of Texas System |
MicroRNA composition for the treatment of neuroblastoma
|
EP3604499A1
(en)
|
2014-03-04 |
2020-02-05 |
Fate Therapeutics, Inc. |
Improved reprogramming methods and cell culture platforms
|
WO2015142910A1
(en)
|
2014-03-17 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
AU2015231130C1
(en)
|
2014-03-19 |
2021-12-23 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating Ataxin 2 expression
|
AU2015240761B2
(en)
|
2014-04-01 |
2019-09-12 |
Biogen Ma Inc. |
Compositions for modulating SOD-1 expression
|
TWI638047B
(en)
|
2014-04-09 |
2018-10-11 |
史基普研究協會 |
Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
|
EP4162940A1
(en)
|
2014-04-17 |
2023-04-12 |
Biogen MA Inc. |
Compositions and methods for modulation of smn2 splicing in a subject
|
US10221416B2
(en)
|
2014-04-24 |
2019-03-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
EP3811977A1
(en)
|
2014-05-01 |
2021-04-28 |
Ionis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
RU2703411C2
(en)
|
2014-05-01 |
2019-10-16 |
Ионис Фармасьютикалз, Инк. |
Compositions and methods for modulating pkk expression
|
CA2946003A1
(en)
|
2014-05-01 |
2015-11-05 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating angiopoietin-like 3 expression
|
ES2812099T3
(en)
|
2014-05-01 |
2021-03-16 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating growth hormone receptor expression
|
BR112016022593B1
(en)
|
2014-05-01 |
2022-04-26 |
Ionis Pharmaceuticals, Inc |
Oligomeric compounds, compositions comprising them, and uses thereof
|
TW201607559A
(en)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
Methods and compositions for treating a SERPINC1-associated disorder
|
AU2015264038B2
(en)
|
2014-05-22 |
2021-02-11 |
Alnylam Pharmaceuticals, Inc. |
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
|
WO2015187541A1
(en)
|
2014-06-02 |
2015-12-10 |
Children's Medical Center Corporation |
Methods and compositions for immunomodulation
|
AU2015269412B2
(en)
|
2014-06-04 |
2020-03-12 |
Exicure Operating Company |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
HRP20220379T1
(en)
|
2014-06-10 |
2022-05-27 |
Erasmus University Medical Center Rotterdam |
Antisense oligonucleotides useful in treatment of pompe disease
|
TW201620526A
(en)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin
|
EP3169310A1
(en)
|
2014-07-15 |
2017-05-24 |
Life Technologies Corporation |
Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
|
CA2955250A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US9951327B1
(en)
|
2014-07-17 |
2018-04-24 |
Integrated Dna Technologies, Inc. |
Efficient and rapid method for assembling and cloning double-stranded DNA fragments
|
WO2016014846A1
(en)
|
2014-07-23 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of intrabodies
|
BR112017001860A2
(en)
|
2014-07-31 |
2018-02-27 |
Uab Research Foundation |
synthetic peptide, pharmaceutical composition, methods, dosage regimen, and monoclonal antibody
|
CN106794256B
(en)
|
2014-08-19 |
2021-04-30 |
西北大学 |
Protein/oligonucleotide core-shell nanoparticle therapeutics
|
US10385343B2
(en)
|
2014-08-29 |
2019-08-20 |
Children's Medical Center Corporation |
Methods and compositions for the treatment of cancer
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
CN113599539A
(en)
|
2014-08-29 |
2021-11-05 |
阿尔尼拉姆医药品有限公司 |
Methods of Treating Transthyretin (TTR) -mediated amyloidosis
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
WO2016044271A2
(en)
|
2014-09-15 |
2016-03-24 |
Children's Medical Center Corporation |
Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
|
AU2015318782A1
(en)
|
2014-09-18 |
2017-04-06 |
The University Of British Columbia |
Allele-specific therapy for Huntington Disease haplotypes
|
JOP20200115A1
(en)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
|
US20170304459A1
(en)
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
EP3904519A1
(en)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
PE20170921A1
(en)
|
2014-11-10 |
2017-07-12 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
LONG-ACTING PHARMACEUTICAL COMPOSITIONS FOR HEPATITIS C
|
EP3218486A1
(en)
|
2014-11-10 |
2017-09-20 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Combination long acting compositions and methods for hepatitis c
|
JOP20200092A1
(en)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
AU2015350120B2
(en)
|
2014-11-17 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
|
WO2016081911A2
(en)
|
2014-11-21 |
2016-05-26 |
Northwestern University |
The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
|
US10400243B2
(en)
|
2014-11-25 |
2019-09-03 |
Ionis Pharmaceuticals, Inc. |
Modulation of UBE3A-ATS expression
|
WO2016100716A1
(en)
|
2014-12-18 |
2016-06-23 |
Vasant Jadhav |
Reversirtm compounds
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
EP3247988A4
(en)
|
2015-01-23 |
2018-12-19 |
Vanderbilt University |
A robust interferometer and methods of using same
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
US11421229B2
(en)
|
2015-02-20 |
2022-08-23 |
Baylor College Of Medicine |
p63 inactivation for the treatment of heart failure
|
US10450342B2
(en)
|
2015-02-23 |
2019-10-22 |
Ionis Pharmaceuticals, Inc. |
Method for solution phase detritylation of oligomeric compounds
|
MX2017011010A
(en)
|
2015-02-26 |
2017-10-20 |
Ionis Pharmaceuticals Inc |
Allele specific modulators of p23h rhodopsin.
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
US20160348073A1
(en)
|
2015-03-27 |
2016-12-01 |
President And Fellows Of Harvard College |
Modified t cells and methods of making and using the same
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
PL3283080T3
(en)
|
2015-04-16 |
2020-07-27 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating c9orf72 expression
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
WO2016195982A2
(en)
|
2015-06-01 |
2016-12-08 |
The Penn State Research Foundation |
Hepatitis b virus capsid assembly
|
WO2016201301A1
(en)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209772A2
(en)
|
2015-06-22 |
2016-12-29 |
Proteovista Llc |
Snp arrays
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
EP3314260B1
(en)
|
2015-06-24 |
2021-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for detecting protein-protein interactions
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
AU2016295168B2
(en)
|
2015-07-17 |
2021-08-19 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
EP3332009A1
(en)
|
2015-08-04 |
2018-06-13 |
Yeda Research and Development Co., Ltd. |
Methods of screening for riboswitches and attenuators
|
KR20180038465A
(en)
|
2015-08-07 |
2018-04-16 |
애로우헤드 파마슈티컬스 인코포레이티드 |
RNAi therapy for hepatitis B virus infection
|
CN114525280A
(en)
|
2015-09-02 |
2022-05-24 |
阿尔尼拉姆医药品有限公司 |
iRNA compositions of programmed cell death 1 ligand 1(PD-L1) and methods of use thereof
|
US10533175B2
(en)
|
2015-09-25 |
2020-01-14 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating Ataxin 3 expression
|
KR20240033305A
(en)
|
2015-10-08 |
2024-03-12 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Compounds and methods for modulating angiotensinogen expression
|
BR112018007611A2
(en)
|
2015-10-14 |
2018-10-23 |
Bio Path Holding Inc |
p-ethoxy nucleic acids for liposome formulation
|
CA3001917A1
(en)
|
2015-10-16 |
2017-04-20 |
Fate Therapeutics, Inc. |
Platform for the induction & maintenance of ground state pluripotency
|
ES2938883T3
(en)
|
2015-11-05 |
2023-04-17 |
Los Angeles Childrens Hospital |
Oligo antisense for use in the treatment of acute myeloid leukemia
|
WO2017079739A1
(en)
|
2015-11-06 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
MODULATING APOLIPOPROTEIN (a) EXPRESSION
|
US11058709B1
(en)
|
2015-12-04 |
2021-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
AU2015416656B2
(en)
|
2015-12-07 |
2023-02-23 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for Pompe disease
|
US11761007B2
(en)
|
2015-12-18 |
2023-09-19 |
The Scripps Research Institute |
Production of unnatural nucleotides using a CRISPR/Cas9 system
|
AU2017205462A1
(en)
|
2016-01-05 |
2018-06-07 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing LRRK2 expression
|
US10627396B2
(en)
|
2016-01-29 |
2020-04-21 |
Vanderbilt University |
Free-solution response function interferometry
|
CN109071625A
(en)
|
2016-02-04 |
2018-12-21 |
柯瑞斯公司 |
Smooth mutant and its application method
|
US10577607B2
(en)
|
2016-03-16 |
2020-03-03 |
Ionis Pharmaceuticals, Inc. |
Modulation of DYRK1B expression
|
CA3013799A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating keap1
|
CA3019635A1
(en)
|
2016-03-31 |
2017-10-05 |
Baylor Research Institute |
Angiopoietin-like protein 8 (angptl8)
|
MA45295A
(en)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP / VIGILINE) RNA COMPOSITION AND METHODS FOR USING THEM
|
JP2019518028A
(en)
|
2016-06-10 |
2019-06-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Complement component C5i RNA composition and its use for treating paroxysmal nocturnal hemoglobinuria (PNH)
|
US11236339B2
(en)
|
2016-06-17 |
2022-02-01 |
Ionis Pharmaceuticals, Inc. |
Modulation of GYS1 expression
|
EP3475295B1
(en)
|
2016-06-24 |
2022-08-10 |
The Scripps Research Institute |
Novel nucleoside triphosphate transporter and uses thereof
|
KR20230088522A
(en)
|
2016-07-21 |
2023-06-19 |
맥스시티 인코포레이티드 |
Methods and compositions for modifying genomic dna
|
JOP20170161A1
(en)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
RNAi Agents for Hepatitis B Virus Infection
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
WO2018039629A2
(en)
|
2016-08-25 |
2018-03-01 |
Northwestern University |
Micellar spherical nucleic acids from thermoresponsive, traceless templates
|
WO2018036503A1
(en)
|
2016-08-25 |
2018-03-01 |
The Chinese University Of Hong Kong |
Fecal bacterial markers for colorectal cancer
|
BR112019005166A2
(en)
|
2016-09-16 |
2019-07-02 |
Bio Path Holding Inc |
combination therapy with liposomal antisense oligonucleotides
|
WO2018055577A1
(en)
|
2016-09-23 |
2018-03-29 |
Synthena Ag |
Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
|
KR20190065341A
(en)
|
2016-10-06 |
2019-06-11 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Method of joining oligomeric compounds
|
JOP20190104A1
(en)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing atxn3 expression
|
TW202313978A
(en)
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
Serpina1 irna compositions and methods of use thereof
|
EP3548620A4
(en)
|
2016-12-02 |
2020-07-22 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
KR20230166146A
(en)
|
2016-12-16 |
2023-12-06 |
알닐람 파마슈티칼스 인코포레이티드 |
Methods for treating or preventing ttr-associated diseases using transthyretin(ttr) irna compositions
|
KR20190098748A
(en)
|
2017-01-10 |
2019-08-22 |
애로우헤드 파마슈티컬스 인코포레이티드 |
Alpha-1 antitrypsin (AAT) RNAi agent, compositions comprising AAT RNAi agent, and methods of use
|
EP3570892A4
(en)
*
|
2017-01-18 |
2020-11-25 |
Alnylam Pharmaceuticals, Inc. |
Endosomal cleavable linkers
|
BR112019014841A2
(en)
|
2017-01-23 |
2020-04-28 |
Regeneron Pharma |
guide rna, use of guide rna, antisense rna, sirna or shrna, use of antisense rna, sirna or shrna, isolated nucleic acid, vector, composition, cell, and, methods to modify an hsd17b13 gene in a cell, to decrease the expression of an hsd17b13 gene in a cell, to modify a cell and to treat an individual who does not carry the hsd17b13 variant
|
WO2018165564A1
(en)
|
2017-03-09 |
2018-09-13 |
Ionis Pharmaceuticals, Inc. |
Morpholino modified oligomeric compounds
|
US11771703B2
(en)
|
2017-03-17 |
2023-10-03 |
The Johns Hopkins University |
Targeted epigenetic therapy against distal regulatory element of TGFβ2 expression
|
WO2018183969A1
(en)
|
2017-03-30 |
2018-10-04 |
California Institute Of Technology |
Barcoded rapid assay platform for efficient analysis of candidate molecules and methods of making and using the platform
|
KR20200015895A
(en)
|
2017-04-18 |
2020-02-13 |
알닐람 파마슈티칼스 인코포레이티드 |
How to treat a subject infected with hepatitis B virus (HBV)
|
JP2020517613A
(en)
|
2017-04-20 |
2020-06-18 |
シンセナ アーゲー |
Modified oligomeric compounds containing tricyclo DNA nucleosides and uses thereof
|
WO2018193428A1
(en)
|
2017-04-20 |
2018-10-25 |
Synthena Ag |
Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
|
AU2018300069A1
(en)
|
2017-07-11 |
2020-02-27 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
EP3652186A4
(en)
|
2017-07-13 |
2021-03-31 |
Northwestern University |
General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles
|
WO2019014530A1
(en)
|
2017-07-13 |
2019-01-17 |
Alnylam Pharmaceuticals Inc. |
Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
|
TWI757528B
(en)
|
2017-08-03 |
2022-03-11 |
美商欣爍克斯公司 |
Cytokine conjugates for the treatment of proliferative and infectious diseases
|
US11197884B2
(en)
|
2017-08-18 |
2021-12-14 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
Modulators of smad7 expression
|
US11806360B2
(en)
|
2017-09-19 |
2023-11-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
|
EP3692073A4
(en)
|
2017-10-03 |
2021-05-26 |
Cedars-Sinai Medical Center |
Methods for targeting the immune checkpoint pd1 pathway for treating pulmonary fibrosis
|
WO2019089922A1
(en)
|
2017-11-01 |
2019-05-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
CA3079524A1
(en)
|
2017-11-03 |
2019-05-09 |
Interna Technologies B.V. |
Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
|
WO2019090205A1
(en)
|
2017-11-06 |
2019-05-09 |
Snap Bio, Inc. |
Pim kinase inhibitor compositions, methods, and uses thereof
|
TWI809004B
(en)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
Compounds and methods for reducing snca expression
|
US20200385719A1
(en)
|
2017-11-16 |
2020-12-10 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
JP2021508491A
(en)
|
2017-12-18 |
2021-03-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
High Mobility Group Box-1 (HMGB1) iRNA Composition and How to Use It
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
CN111902537A
(en)
|
2018-01-15 |
2020-11-06 |
Ionis制药公司 |
Modulators of DNM2 expression
|
US20190233816A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
US20210038732A1
(en)
|
2018-02-12 |
2021-02-11 |
Interna Technologies B.V. |
Anticancer microrna and lipid formulations thereof
|
KR20200127207A
(en)
|
2018-02-26 |
2020-11-10 |
신톡스, 인크. |
IL-15 conjugate and uses thereof
|
WO2019169243A1
(en)
|
2018-03-02 |
2019-09-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-beta precursor protein
|
BR112020016001A2
(en)
|
2018-03-02 |
2020-12-15 |
Ionis Pharmaceuticals, Inc. |
IRF4 EXPRESSION MODULATORS
|
WO2019183440A1
(en)
|
2018-03-22 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
CA3096274A1
(en)
|
2018-04-06 |
2019-10-10 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
CN112041440A
(en)
|
2018-04-11 |
2020-12-04 |
Ionis制药公司 |
Modulators of EZH2 expression
|
BR112020022546A8
(en)
|
2018-05-07 |
2022-05-17 |
Alnylam Pharmaceuticals Inc |
extra-hepatic delivery
|
SG11202010215TA
(en)
|
2018-05-09 |
2020-11-27 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing atxn3 expression
|
CU20200082A7
(en)
|
2018-05-09 |
2021-06-08 |
Ionis Pharmaceuticals Inc |
COMPOUNDS AND METHODS FOR REDUCING THE EXPRESSION OF FXI
|
TW202016304A
(en)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
CA3103429A1
(en)
|
2018-06-14 |
2019-12-19 |
Don W. Cleveland |
Compounds and methods for increasing stmn2 expression
|
WO2020006267A1
(en)
|
2018-06-27 |
2020-01-02 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing lrrk2 expression
|
AR115847A1
(en)
|
2018-07-25 |
2021-03-03 |
Ionis Pharmaceuticals Inc |
COMPOUNDS AND METHODS TO REDUCE THE EXPRESSION OF ATXN2
|
EP3833762A4
(en)
|
2018-08-09 |
2022-09-28 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
SG11202100715WA
(en)
|
2018-08-13 |
2021-02-25 |
Alnylam Pharmaceuticals Inc |
HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
TW202020157A
(en)
|
2018-08-16 |
2020-06-01 |
美商艾爾妮蘭製藥公司 |
Compositions and methods for inhibiting expression of the lect2 gene
|
CA3112793A1
(en)
|
2018-09-14 |
2020-03-19 |
Northwestern University |
Programming protein polymerization with dna
|
JP2022500003A
(en)
|
2018-09-18 |
2022-01-04 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Ketohexokinase (KHK) iRNA composition and its usage
|
WO2020069055A1
(en)
|
2018-09-28 |
2020-04-02 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
US20210395751A1
(en)
|
2018-10-31 |
2021-12-23 |
The University Of Sydney |
Compositions and methods for treating viral infections
|
WO2020097261A1
(en)
|
2018-11-06 |
2020-05-14 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
New compositions and methods for treating beta-globinopathies
|
TW202028222A
(en)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Modulators of foxp3 expression
|
AU2019380940A1
(en)
|
2018-11-15 |
2021-06-03 |
Ionis Pharmaceuticals, Inc. |
Modulators of IRF5 expression
|
WO2020118259A1
(en)
|
2018-12-06 |
2020-06-11 |
Northwestern University |
Protein crystal engineering through dna hybridization interactions
|
TW202039000A
(en)
|
2018-12-20 |
2020-11-01 |
瑞士商休曼斯生物醫藥公司 |
Combination hbv therapy
|
AU2019406186A1
(en)
|
2018-12-20 |
2021-07-15 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of KCNT1 related disorders
|
CN113557023A
(en)
|
2019-01-16 |
2021-10-26 |
建新公司 |
Serpinc1 iRNA compositions and methods of use thereof
|
KR20210122809A
(en)
|
2019-01-31 |
2021-10-12 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Regulators of YAP1 expression
|
AU2020218203A1
(en)
|
2019-02-06 |
2021-08-26 |
Synthorx, Inc. |
IL-2 conjugates and methods of use thereof
|
BR112021015323A2
(en)
|
2019-02-27 |
2021-10-05 |
Ionis Pharmaceuticals, Inc. |
MALAT1 EXPRESSION MODULATORS
|
CA3135579A1
(en)
|
2019-03-29 |
2020-10-08 |
Mitsubishi Tanabe Pharma Corporation |
Compound, method and pharmaceutical composition for modulating expression of dux4
|
WO2020205463A1
(en)
|
2019-03-29 |
2020-10-08 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating ube3a-ats
|
CN114126628A
(en)
|
2019-05-13 |
2022-03-01 |
维尔生物科技有限公司 |
Compositions and methods for treating Hepatitis B Virus (HBV) infection
|
JP2022532652A
(en)
|
2019-05-17 |
2022-07-15 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
Oral delivery of oligonucleotides
|
TW202113078A
(en)
|
2019-06-14 |
2021-04-01 |
美商史基普研究協會 |
Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
|
US20220305117A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
|
CN114340663A
(en)
|
2019-06-18 |
2022-04-12 |
爱尔兰詹森科学公司 |
Combination of Hepatitis B Virus (HBV) vaccine and HBV-targeted RNAi
|
EP3956450A4
(en)
|
2019-07-26 |
2022-11-16 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
EP4007812A1
(en)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
EP4013767A4
(en)
|
2019-08-15 |
2023-10-25 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds and uses thereof
|
CN114555128A
(en)
|
2019-08-15 |
2022-05-27 |
新索思股份有限公司 |
Combination immunooncology therapy with IL-2 conjugates
|
MX2022002053A
(en)
|
2019-08-23 |
2022-03-17 |
Synthorx Inc |
Il-15 conjugates and uses thereof.
|
US20220290152A1
(en)
|
2019-09-03 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
KR20220061158A
(en)
|
2019-09-10 |
2022-05-12 |
신톡스, 인크. |
IL-2 conjugates and methods of use for treating autoimmune diseases
|
US20220389429A1
(en)
|
2019-10-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
EP4045652A1
(en)
|
2019-10-18 |
2022-08-24 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
TW202134435A
(en)
|
2019-10-22 |
2021-09-16 |
美商阿尼拉製藥公司 |
Complement component c3 irna compositions and methods of use thereof
|
EP4051796A1
(en)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
TW202132567A
(en)
|
2019-11-01 |
2021-09-01 |
美商阿尼拉製藥公司 |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
TW202131952A
(en)
|
2019-11-04 |
2021-09-01 |
美商欣爍克斯公司 |
Interleukin 10 conjugates and uses thereof
|
JP2023500681A
(en)
|
2019-11-06 |
2023-01-10 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
extrahepatic delivery
|
WO2021092145A1
(en)
|
2019-11-06 |
2021-05-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
EP4061945A1
(en)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
KR20220115995A
(en)
|
2019-12-13 |
2022-08-19 |
알닐람 파마슈티칼스 인코포레이티드 |
Human chromosome 9 open reading frame 72 (C9orf72) iRNA preparation compositions and methods of using the same
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
US20230057461A1
(en)
|
2020-01-27 |
2023-02-23 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
IL295445A
(en)
|
2020-02-10 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for silencing vegf-a expression
|
MX2022010052A
(en)
|
2020-02-18 |
2022-09-05 |
Alnylam Pharmaceuticals Inc |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof.
|
CR20220485A
(en)
|
2020-02-28 |
2022-11-10 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating smn2
|
EP4114947A1
(en)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
WO2021178736A1
(en)
|
2020-03-06 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
EP4121534A1
(en)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
WO2021195307A1
(en)
|
2020-03-26 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
EP4127171A2
(en)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
CA3179411A1
(en)
|
2020-04-06 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
CN116134135A
(en)
|
2020-04-07 |
2023-05-16 |
阿尔尼拉姆医药品有限公司 |
Compositions and methods for silencing SCN9A expression
|
US11965162B2
(en)
|
2020-04-16 |
2024-04-23 |
The Johns Hopkins University |
MicroRNA and inhibitors thereof and methods of treatment
|
CA3181400A1
(en)
|
2020-04-27 |
2021-11-04 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
|
WO2021222549A1
(en)
|
2020-04-30 |
2021-11-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
TW202206596A
(en)
|
2020-05-01 |
2022-02-16 |
美商Ionis製藥公司 |
Compounds and methods for modulating atxn1
|
CN115667513A
(en)
|
2020-05-12 |
2023-01-31 |
田边三菱制药株式会社 |
Compounds, methods and pharmaceutical compositions for modulating Ataxin 3 expression
|
WO2021231675A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
EP4150087A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
EP4150078A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
EP4150077A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
EP4150089A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
|
EP4153746A1
(en)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
AR122534A1
(en)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY
|
EP4161552A1
(en)
|
2020-06-05 |
2023-04-12 |
The Broad Institute, Inc. |
Compositions and methods for treating neoplasia
|
WO2021252557A1
(en)
|
2020-06-09 |
2021-12-16 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
BR112022024420A2
(en)
|
2020-06-18 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
XANTHINE DEHYDROGENASE (XDH) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
AU2021296848A1
(en)
|
2020-06-24 |
2023-02-09 |
Humabs Biomed Sa |
Engineered hepatitis B virus neutralizing antibodies and uses thereof
|
IL299074A
(en)
|
2020-06-25 |
2023-02-01 |
Synthorx Inc |
Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodies
|
BR112022024206A2
(en)
|
2020-06-29 |
2023-01-03 |
Ionis Pharmaceuticals Inc |
COMPOUNDS AND METHODS TO MODULATE PLP1
|
WO2022011214A1
(en)
|
2020-07-10 |
2022-01-13 |
Alnylam Pharmaceuticals, Inc. |
Circular sirnas
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
EP4225917A1
(en)
|
2020-10-05 |
2023-08-16 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
EP3978608A1
(en)
|
2020-10-05 |
2022-04-06 |
SQY Therapeutics |
Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51
|
KR20230084204A
(en)
|
2020-10-09 |
2023-06-12 |
신톡스, 인크. |
Immuno-oncology therapy using IL-2 conjugates
|
CA3194859A1
(en)
|
2020-10-09 |
2022-04-14 |
Carolina E. CAFFARO |
Immuno oncology combination therapy with il-2 conjugates and pembrolizumab
|
AU2021365822A1
(en)
|
2020-10-21 |
2023-06-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
WO2022087329A1
(en)
|
2020-10-23 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
IL302709A
(en)
|
2020-11-13 |
2023-07-01 |
Alnylam Pharmaceuticals Inc |
COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
US11447521B2
(en)
|
2020-11-18 |
2022-09-20 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
EP4256053A1
(en)
|
2020-12-01 |
2023-10-11 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
WO2022125490A1
(en)
|
2020-12-08 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
WO2022140702A1
(en)
|
2020-12-23 |
2022-06-30 |
Flagship Pioneering, Inc. |
Compositions of modified trems and uses thereof
|
EP4271696A2
(en)
|
2020-12-31 |
2023-11-08 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
WO2022147223A2
(en)
|
2020-12-31 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
2'-modified nucleoside based oligonucleotide prodrugs
|
EP4274896A1
(en)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component 9 (c9) irna compositions and methods of use thereof
|
WO2022174101A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Skin cancer combination therapy with il-2 conjugates and cemiplimab
|
TW202302148A
(en)
|
2021-02-12 |
2023-01-16 |
美商欣爍克斯公司 |
Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
|
JP2024508714A
(en)
|
2021-02-12 |
2024-02-28 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Superoxide dismutase 1 (SOD1) iRNA composition and method for using the same for treating or preventing superoxide dismutase 1- (SOD1-) related neurodegenerative diseases
|
JP2024509783A
(en)
|
2021-02-25 |
2024-03-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Prion protein (PRNP) IRNA compositions and methods of use thereof
|
KR20230150844A
(en)
|
2021-02-26 |
2023-10-31 |
알닐람 파마슈티칼스 인코포레이티드 |
Ketohexokinase (KHK) iRNA compositions and methods of using the same
|
CA3212128A1
(en)
|
2021-03-04 |
2022-09-09 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
EP4304640A1
(en)
|
2021-03-12 |
2024-01-17 |
Northwestern University |
Antiviral vaccines using spherical nucleic acids
|
WO2022212231A2
(en)
|
2021-03-29 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
IL307298A
(en)
|
2021-03-31 |
2023-11-01 |
Entrada Therapeutics Inc |
Cyclic cell penetrating peptides
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
IL307926A
(en)
|
2021-04-26 |
2023-12-01 |
Alnylam Pharmaceuticals Inc |
Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
|
EP4330396A1
(en)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
WO2022235537A1
(en)
|
2021-05-03 |
2022-11-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
|
IL308353A
(en)
|
2021-05-10 |
2024-01-01 |
Entrada Therapeutics Inc |
Compositions and methods for modulating tissue distribution of intracellular therapeutics
|
CA3217463A1
(en)
|
2021-05-10 |
2022-11-17 |
Ziqing QIAN |
Compositions and methods for modulating mrna splicing
|
WO2022240721A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
EP4341405A1
(en)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
EP4347823A1
(en)
|
2021-06-02 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
TW202313679A
(en)
|
2021-06-03 |
2023-04-01 |
美商欣爍克斯公司 |
Head and neck cancer combination therapy comprising an il-2 conjugate and a pd-1 antagonist
|
CN117561334A
(en)
|
2021-06-04 |
2024-02-13 |
阿尔尼拉姆医药品有限公司 |
Human chromosome 9 open reading frame 72 (C9 ORF 72) iRNA pharmaceutical compositions and methods of use thereof
|
WO2022260939A2
(en)
|
2021-06-08 |
2022-12-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
CN117500815A
(en)
|
2021-06-18 |
2024-02-02 |
Ionis制药公司 |
Compounds and methods for reducing IFNAR1 expression
|
AU2022298774A1
(en)
|
2021-06-23 |
2023-12-14 |
Entrada Therapeutics, Inc. |
Antisense compounds and methods for targeting cug repeats
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
WO2023003805A1
(en)
|
2021-07-19 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
|
AU2022314619A1
(en)
|
2021-07-21 |
2024-01-04 |
Alnylam Pharmaceuticals, Inc. |
Metabolic disorder-associated target gene irna compositions and methods of use thereof
|
WO2023003995A1
(en)
|
2021-07-23 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
WO2023014677A1
(en)
|
2021-08-03 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
KR20240042016A
(en)
|
2021-08-04 |
2024-04-01 |
알닐람 파마슈티칼스 인코포레이티드 |
iRNA compositions and methods for silencing angiotensinogen (AGT)
|
IL310407A
(en)
|
2021-08-13 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Factor xii (f12) irna compositions and methods of use thereof
|
CA3229661A1
(en)
|
2021-09-01 |
2023-03-09 |
Xiang Li |
Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
CA3232420A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023064530A1
(en)
|
2021-10-15 |
2023-04-20 |
Alnylam Pharmaceuticals, Inc. |
Extra-hepatic delivery irna compositions and methods of use thereof
|
CA3234835A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
TW202334418A
(en)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
CA3234636A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
WO2023081167A2
(en)
|
2021-11-02 |
2023-05-11 |
The Regents Of The University Of California |
P-selectin mutants and modulation of integrin-mediated signaling
|
WO2023092060A1
(en)
|
2021-11-18 |
2023-05-25 |
Cornell University |
Microrna-dependent mrna switches for tissue-specific mrna-based therapies
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023146807A1
(en)
|
2022-01-25 |
2023-08-03 |
The Regents Of The University Of California |
Vegf mutants and modulation of integrin-mediated signaling
|
WO2023220744A2
(en)
|
2022-05-13 |
2023-11-16 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
WO2024006999A2
(en)
|
2022-06-30 |
2024-01-04 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024073732A1
(en)
|
2022-09-30 |
2024-04-04 |
Alnylam Pharmaceuticals, Inc. |
Modified double-stranded rna agents
|